메뉴 건너뛰기




Volumn 10, Issue 5, 2017, Pages 600-624

Complement C5-inhibiting therapy for the thrombotic microangiopathies: Accumulating evidence, but not a panacea

Author keywords

Atypical haemolytic uraemic syndrome; Complement; Eculizumab; Thrombotic microangiopathy

Indexed keywords

COBALAMIN; COMPLEMENT COMPONENT C5; CYCLOSPORIN A; GEMCITABINE; INTERFERON; MITOMYCIN; QUININE; RAPAMYCIN; TACROLIMUS;

EID: 85037973240     PISSN: 20488505     EISSN: 20488513     Source Type: Journal    
DOI: 10.1093/ckj/sfx081     Document Type: Review
Times cited : (44)

References (356)
  • 1
    • 0037158606 scopus 로고    scopus 로고
    • Thrombotic microangiopathies
    • Moake JL. Thrombotic microangiopathies. N Engl J Med 2002;347:589-600
    • (2002) N Engl J Med , vol.347 , pp. 589-600
    • Moake, J.L.1
  • 2
    • 77955883153 scopus 로고    scopus 로고
    • Complement: A key system for immune surveillance and homeostasis
    • Ricklin D et al. Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010;11:785-797
    • (2010) Nat Immunol , vol.11 , pp. 785-797
    • Ricklin, D.1
  • 5
    • 84948716605 scopus 로고    scopus 로고
    • Complement, a target for therapy in inflammatory and degenerative diseases
    • Morgan BP, Harris CL. Complement, a target for therapy in inflammatory and degenerative diseases. Nat Rev Drug Discov 2015;14:857-877
    • (2015) Nat Rev Drug Discov , vol.14 , pp. 857-877
    • Morgan, B.P.1    Harris, C.L.2
  • 6
    • 0030441149 scopus 로고    scopus 로고
    • Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv
    • Thomas TC et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol 1996;33:1389-1401
    • (1996) Mol Immunol , vol.33 , pp. 1389-1401
    • Thomas, T.C.1
  • 7
    • 0036667136 scopus 로고    scopus 로고
    • Eculizumab (Alexion)
    • Kaplan M. Eculizumab (Alexion). Curr Opin Invest Drugs 2002;3:1017-1023
    • (2002) Curr Opin Invest Drugs , vol.3 , pp. 1017-1023
    • Kaplan, M.1
  • 8
    • 10744228553 scopus 로고    scopus 로고
    • Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria
    • Hillmen P et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2004;350:552-559
    • (2004) N Engl J Med , vol.350 , pp. 552-559
    • Hillmen, P.1
  • 9
    • 84991765484 scopus 로고    scopus 로고
    • Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future
    • Risitano AM, Marotta S. Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future. Semin Immunol 2016;28:223-240
    • (2016) Semin Immunol , vol.28 , pp. 223-240
    • Risitano, A.M.1    Marotta, S.2
  • 10
    • 84921387621 scopus 로고    scopus 로고
    • Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome
    • Wong EK, Kavanagh D. Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Transl Res 2015;165:306-320
    • (2015) Transl Res , vol.165 , pp. 306-320
    • Wong, E.K.1    Kavanagh, D.2
  • 11
    • 59449088846 scopus 로고    scopus 로고
    • Eculizumab for congenital atypical hemolytic-uremic syndrome
    • Gruppo RA, Rother RP. Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med 2009;360:544-546
    • (2009) N Engl J Med , vol.360 , pp. 544-546
    • Gruppo, R.A.1    Rother, R.P.2
  • 12
    • 59449107473 scopus 로고    scopus 로고
    • Eculizumab for atypical hemolyticuremic syndrome
    • Nurnberger J et al. Eculizumab for atypical hemolyticuremic syndrome. N Engl JMed 2009;360:542-544
    • (2009) N Engl JMed , vol.360 , pp. 542-544
    • Nurnberger, J.1
  • 13
    • 84878589219 scopus 로고    scopus 로고
    • Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome
    • Legendre CM et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013;368:2169-2181
    • (2013) N Engl J Med , vol.368 , pp. 2169-2181
    • Legendre, C.M.1
  • 14
    • 84973365170 scopus 로고    scopus 로고
    • Infections associated with the use of eculizumab: Recommendations for prevention and prophylaxis
    • Benamu E, Montoya JG. Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis. Curr Opin Infect Dis 2016;29:319-329
    • (2016) Curr Opin Infect Dis , vol.29 , pp. 319-329
    • Benamu, E.1    Montoya, J.G.2
  • 15
    • 85017234165 scopus 로고    scopus 로고
    • Atypical hemolytic uremic syndrome and C3 glomerulopathy: Conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference
    • Goodship TH et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int 2016
    • (2016) Kidney Int
    • Goodship, T.H.1
  • 16
    • 84930607950 scopus 로고    scopus 로고
    • Case report: Benefits and challenges of long-term eculizumab in atypical hemolytic uremic syndrome
    • Cullinan N et al. Case report: benefits and challenges of long-term eculizumab in atypical hemolytic uremic syndrome. Pediatrics 2015;135:e1506-e1509
    • (2015) Pediatrics , vol.135 , pp. e1506-e1509
    • Cullinan, N.1
  • 17
    • 84874435634 scopus 로고    scopus 로고
    • Meningococcal sepsis complicating eculizumab treatment despite prior vaccination
    • Struijk GH et al. Meningococcal sepsis complicating eculizumab treatment despite prior vaccination. Am J Transplant 2013;13:819-820
    • (2013) Am J Transplant , vol.13 , pp. 819-820
    • Struijk, G.H.1
  • 18
    • 84956764057 scopus 로고    scopus 로고
    • Eculizumab-related progressive multifocal leukoencephalopathy
    • Gomez-Cibeira E et al. Eculizumab-related progressive multifocal leukoencephalopathy. Neurology 2016;86:399-400
    • (2016) Neurology , vol.86 , pp. 399-400
    • Gomez-Cibeira, E.1
  • 19
    • 84939974908 scopus 로고    scopus 로고
    • Eculizumab hepatotoxicity in pediatric aHUS
    • Hayes W et al. Eculizumab hepatotoxicity in pediatric aHUS. Pediatr Nephrol 2015;30:775-781
    • (2015) Pediatr Nephrol , vol.30 , pp. 775-781
    • Hayes, W.1
  • 20
    • 84863512960 scopus 로고    scopus 로고
    • Pathology after eculizumab in dense deposit disease and C3 GN
    • Herlitz LC et al. Pathology after eculizumab in dense deposit disease and C3 GN. J AmSoc Nephrol 2012;23:1229-1237
    • (2012) J AmSoc Nephrol , vol.23 , pp. 1229-1237
    • Herlitz, L.C.1
  • 21
    • 85037985917 scopus 로고    scopus 로고
    • Rare genetic variants in Shiga toxin-associated haemolytic uraemic syndrome: Genetic analysis prior to transplantation is essential
    • Dowen F, Wood K, Brown AL et al. Rare genetic variants in Shiga toxin-associated haemolytic uraemic syndrome: genetic analysis prior to transplantation is essential. Clin Kidney J 2017
    • (2017) Clin Kidney J
    • Dowen, F.1    Wood, K.2    Brown, A.L.3
  • 22
    • 84906077328 scopus 로고    scopus 로고
    • Syndromes of thrombotic microangiopathy
    • George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med 2014;371:654-666
    • (2014) N Engl J Med , vol.371 , pp. 654-666
    • George, J.N.1    Nester, C.M.2
  • 23
    • 84936985706 scopus 로고    scopus 로고
    • Atypical aHUS: State of the art
    • Nester CM et al. Atypical aHUS: State of the art. Mol Immunol 2015;67:31-42
    • (2015) Mol Immunol , vol.67 , pp. 31-42
    • Nester, C.M.1
  • 24
    • 84965057545 scopus 로고    scopus 로고
    • The alternative pathway of complement and the thrombotic microangiopathies
    • Teoh CW, Riedl M, Licht C. The alternative pathway of complement and the thrombotic microangiopathies. Transfus Apher Sci 2016;54:220-231
    • (2016) Transfus Apher Sci , vol.54 , pp. 220-231
    • Teoh, C.W.1    Riedl, M.2    Licht, C.3
  • 25
    • 0031970553 scopus 로고    scopus 로고
    • Genetic studies into inherited and sporadic hemolytic uremic syndrome
    • Warwicker P et al. Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int 1998;53:836-844
    • (1998) Kidney Int , vol.53 , pp. 836-844
    • Warwicker, P.1
  • 26
    • 84876044818 scopus 로고    scopus 로고
    • Genetics and outcome of atypical hemolytic uremic syndrome: A nationwide French series comparing children and adults
    • Fremeaux-Bacchi V et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 2013;8:554-562
    • (2013) Clin J Am Soc Nephrol , vol.8 , pp. 554-562
    • Fremeaux-Bacchi, V.1
  • 27
    • 77958587405 scopus 로고    scopus 로고
    • Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype
    • Noris M et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010;5:1844-1859
    • (2010) Clin J Am Soc Nephrol , vol.5 , pp. 1844-1859
    • Noris, M.1
  • 28
    • 34548309310 scopus 로고    scopus 로고
    • Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome
    • Kavanagh D et al. Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome. Mol Immunol 2008;45:95-105
    • (2008) Mol Immunol , vol.45 , pp. 95-105
    • Kavanagh, D.1
  • 29
    • 67449119124 scopus 로고    scopus 로고
    • The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome
    • Ferreira VP et al. The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome. J Immunol 2009;182:7009-7018
    • (2009) J Immunol , vol.182 , pp. 7009-7018
    • Ferreira, V.P.1
  • 30
    • 33747159590 scopus 로고    scopus 로고
    • Genetics of HUS: The impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome
    • Caprioli J et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006;108:1267-1279
    • (2006) Blood , vol.108 , pp. 1267-1279
    • Caprioli, J.1
  • 31
    • 20544437666 scopus 로고    scopus 로고
    • Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome
    • Dragon-Durey MA et al. Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 2005;16:555-563
    • (2005) J Am Soc Nephrol , vol.16 , pp. 555-563
    • Dragon-Durey, M.A.1
  • 32
    • 75649133611 scopus 로고    scopus 로고
    • Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome
    • Moore I et al. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood 2010;115:379-387
    • (2010) Blood , vol.115 , pp. 379-387
    • Moore, I.1
  • 33
    • 84858029055 scopus 로고    scopus 로고
    • Factor I autoantibodies in patients with atypical hemolytic uremic syndrome: Disease-associated or an epiphenomenon?
    • Kavanagh D et al. Factor I autoantibodies in patients with atypical hemolytic uremic syndrome: disease-associated or an epiphenomenon? ClinJ AmSoc Nephrol 2012;7:417-426
    • (2012) ClinJ AmSoc Nephrol , vol.7 , pp. 417-426
    • Kavanagh, D.1
  • 34
    • 84929629467 scopus 로고    scopus 로고
    • Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: One target, two diseases
    • Blanc C et al. Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: one target, two diseases. J Immunol 2015;194:5129-5138
    • (2015) J Immunol , vol.194 , pp. 5129-5138
    • Blanc, C.1
  • 35
    • 84899769165 scopus 로고    scopus 로고
    • Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children
    • Sinha A et al. Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children. Kidney Int 2014;85:1151-1160
    • (2014) Kidney Int , vol.85 , pp. 1151-1160
    • Sinha, A.1
  • 36
    • 84866556872 scopus 로고    scopus 로고
    • Overall neutralization of complement factor H by autoantibodies in the acute phase of the autoimmune form of atypical hemolytic uremic syndrome
    • Blanc C et al. Overall neutralization of complement factor H by autoantibodies in the acute phase of the autoimmune form of atypical hemolytic uremic syndrome. J Immunol 2012;189:3528-3537
    • (2012) J Immunol , vol.189 , pp. 3528-3537
    • Blanc, C.1
  • 37
    • 84929128976 scopus 로고    scopus 로고
    • Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies
    • Licht C et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int 2015;87:1061-1073
    • (2015) Kidney Int , vol.87 , pp. 1061-1073
    • Licht, C.1
  • 38
    • 84975266700 scopus 로고    scopus 로고
    • Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: A single-arm, open-label trial
    • Fakhouri F et al. Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial. Am J Kidney Dis 2016;68:84-93
    • (2016) Am J Kidney Dis , vol.68 , pp. 84-93
    • Fakhouri, F.1
  • 39
    • 84964561130 scopus 로고    scopus 로고
    • Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome
    • Greenbaum LA et al. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int 2016;89:701-711
    • (2016) Kidney Int , vol.89 , pp. 701-711
    • Greenbaum, L.A.1
  • 40
    • 85025842535 scopus 로고    scopus 로고
    • Factor H autoantibody associated atypical haemolytic uraemic syndrome in children in the United Kingdom and Ireland (2000-2015)
    • Brocklebank V, Johnson S, Sheerin TP et al. Factor H autoantibody associated atypical haemolytic uraemic syndrome in children in the United Kingdom and Ireland (2000-2015). Kidney Int 2017
    • (2017) Kidney Int
    • Brocklebank, V.1    Johnson, S.2    Sheerin, T.P.3
  • 41
    • 84876741397 scopus 로고    scopus 로고
    • Changing strategies for organ transplantation in atypical haemolytic uraemic syndrome: A tertiary case series
    • Forbes TA et al. Changing strategies for organ transplantation in atypical haemolytic uraemic syndrome: a tertiary case series. Pediatr Transplant 2013;17:E93-E99
    • (2013) Pediatr Transplant , vol.17 , pp. E93-E99
    • Forbes, T.A.1
  • 42
    • 84964480157 scopus 로고    scopus 로고
    • A national specialized service in England for atypical haemolytic uraemic syndrome-the first year's experience
    • Sheerin NS et al. A national specialized service in England for atypical haemolytic uraemic syndrome-the first year's experience. QJM 2016;109:27-33
    • (2016) QJM , vol.109 , pp. 27-33
    • Sheerin, N.S.1
  • 43
    • 84870534251 scopus 로고    scopus 로고
    • Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation
    • Zuber J et al. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant 2012;12:3337-3354
    • (2012) Am J Transplant , vol.12 , pp. 3337-3354
    • Zuber, J.1
  • 44
    • 84917673672 scopus 로고    scopus 로고
    • Atypical hemolytic uremic syndrome recurrence after kidney transplantation
    • Matar D et al. Atypical hemolytic uremic syndrome recurrence after kidney transplantation. Transplantation 2014;98:1205-1212
    • (2014) Transplantation , vol.98 , pp. 1205-1212
    • Matar, D.1
  • 45
    • 79958202220 scopus 로고    scopus 로고
    • Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome
    • Nester C et al. Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2011;6:1488-1494
    • (2011) Clin J Am Soc Nephrol , vol.6 , pp. 1488-1494
    • Nester, C.1
  • 46
    • 77951876953 scopus 로고    scopus 로고
    • Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome
    • Zimmerhackl LB et al. Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome. N Engl JMed 2010;362:1746-1748
    • (2010) N Engl JMed , vol.362 , pp. 1746-1748
    • Zimmerhackl, L.B.1
  • 47
    • 84863208524 scopus 로고    scopus 로고
    • Renal transplantation under prophylactic eculizumab in atypical hemolytic uremic syndrome with CFH/CFHR1 hybrid protein
    • Krid S et al. Renal transplantation under prophylactic eculizumab in atypical hemolytic uremic syndrome with CFH/CFHR1 hybrid protein. Am J Transplant 2012;12:1938-1944
    • (2012) Am J Transplant , vol.12 , pp. 1938-1944
    • Krid, S.1
  • 48
    • 80052473232 scopus 로고    scopus 로고
    • Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome
    • Weitz M et al. Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome. Pediatr Nephrol 2011;26:1325-1329
    • (2011) Pediatr Nephrol , vol.26 , pp. 1325-1329
    • Weitz, M.1
  • 49
    • 84890562904 scopus 로고    scopus 로고
    • Eculizumab long-term therapy for pediatric renal transplant in aHUS with CFH/CFHR1 hybrid gene
    • Roman-Ortiz E et al. Eculizumab long-term therapy for pediatric renal transplant in aHUS with CFH/CFHR1 hybrid gene. Pediatr Nephrol 2014;29:149-153
    • (2014) Pediatr Nephrol , vol.29 , pp. 149-153
    • Roman-Ortiz, E.1
  • 50
    • 84883374274 scopus 로고    scopus 로고
    • Anti-C5 as prophylactic therapy in atypical hemolytic uremic syndrome in living-related kidney transplantation
    • Pelicano MB et al. Anti-C5 as prophylactic therapy in atypical hemolytic uremic syndrome in living-related kidney transplantation. Transplantation 2013;96:e26-e29
    • (2013) Transplantation , vol.96 , pp. e26-e29
    • Pelicano, M.B.1
  • 51
    • 84906097193 scopus 로고    scopus 로고
    • Prophylactic eculizumab for kidney transplantation in a child with atypical hemolytic uremic syndrome due to complement factor H mutation
    • Ranch D et al. Prophylactic eculizumab for kidney transplantation in a child with atypical hemolytic uremic syndrome due to complement factor H mutation. Pediatr Transplant 2014;18:E185-E189
    • (2014) Pediatr Transplant , vol.18 , pp. E185-E189
    • Ranch, D.1
  • 52
    • 84870161966 scopus 로고    scopus 로고
    • Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: A case report
    • Xie L et al. Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report. Transplant Proc 2012;44:3037-3040
    • (2012) Transplant Proc , vol.44 , pp. 3037-3040
    • Xie, L.1
  • 53
    • 84942924628 scopus 로고    scopus 로고
    • Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: The experience of the Australian compassionate access cohort
    • Mallett A et al. Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort. Intern Med J 2015;45:1054-1065
    • (2015) Intern Med J , vol.45 , pp. 1054-1065
    • Mallett, A.1
  • 54
    • 84995799460 scopus 로고    scopus 로고
    • Prevention of recurrence of atypical hemolytic uremic syndrome post renal transplant with the use of higher-dose eculizumab
    • Riddell A, Goodship T, Bingham C. Prevention of recurrence of atypical hemolytic uremic syndrome post renal transplant with the use of higher-dose eculizumab. Clin Nephrol 2016;86:200-202
    • (2016) Clin Nephrol , vol.86 , pp. 200-202
    • Riddell, A.1    Goodship, T.2    Bingham, C.3
  • 55
    • 84894107600 scopus 로고    scopus 로고
    • Liver-kidney transplantation to cure atypical HUS: Still an option post-eculizumab?
    • Saland J. Liver-kidney transplantation to cure atypical HUS: still an option post-eculizumab? Pediatr Nephrol 2014;29:329-332
    • (2014) Pediatr Nephrol , vol.29 , pp. 329-332
    • Saland, J.1
  • 56
    • 33644914494 scopus 로고    scopus 로고
    • Calcineurin inhibitor-free immunosuppression in renal allograft recipients with thrombotic microangiopathy/hemolytic uremic syndrome
    • Oyen O et al. Calcineurin inhibitor-free immunosuppression in renal allograft recipients with thrombotic microangiopathy/hemolytic uremic syndrome. Am J Transplant 2006;6:412-418
    • (2006) Am J Transplant , vol.6 , pp. 412-418
    • Oyen, O.1
  • 57
    • 70350130833 scopus 로고    scopus 로고
    • Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome
    • Chatelet V et al. Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome. Am J Transplant 2009;9:2644-2645
    • (2009) Am J Transplant , vol.9 , pp. 2644-2645
    • Chatelet, V.1
  • 58
    • 84863724130 scopus 로고    scopus 로고
    • Eculizumab for the treatment of two recurrences of atypical hemolytic uremic syndrome in a kidney allograft
    • Alachkar N, Bagnasco SM, Montgomery RA. Eculizumab for the treatment of two recurrences of atypical hemolytic uremic syndrome in a kidney allograft. Transpl Int 2012;25:e93-e95
    • (2012) Transpl Int , vol.25 , pp. e93-e95
    • Alachkar, N.1    Bagnasco, S.M.2    Montgomery, R.A.3
  • 59
    • 84868003869 scopus 로고    scopus 로고
    • Rescue therapy with eculizumab in a transplant recipient with atypical haemolytic-uraemic syndrome
    • Duran CE et al. Rescue therapy with eculizumab in a transplant recipient with atypical haemolytic-uraemic syndrome. Clin Kidney J 2012;5:28-30
    • (2012) Clin Kidney J , vol.5 , pp. 28-30
    • Duran, C.E.1
  • 60
    • 84940991737 scopus 로고    scopus 로고
    • Thrombotic microangiopathy as a cause of chronic kidney transplant dysfunction: Case report demonstrating successful treatment with eculizumab
    • Iqbal Z et al. Thrombotic microangiopathy as a cause of chronic kidney transplant dysfunction: case report demonstrating successful treatment with eculizumab. Transplant Proc 2015;47:2258-2261
    • (2015) Transplant Proc , vol.47 , pp. 2258-2261
    • Iqbal, Z.1
  • 61
    • 77950955452 scopus 로고    scopus 로고
    • Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation
    • Larrea CF et al. Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation. Transplantation 2010;89:903-904
    • (2010) Transplantation , vol.89 , pp. 903-904
    • Larrea, C.F.1
  • 62
    • 77949570344 scopus 로고    scopus 로고
    • Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation
    • Davin JC et al. Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation. Am J Kidney Dis 2010;55:708-711
    • (2010) Am J Kidney Dis , vol.55 , pp. 708-711
    • Davin, J.C.1
  • 63
    • 84874417661 scopus 로고    scopus 로고
    • Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome
    • Le Quintrec M et al. Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant 2013;13:663-675
    • (2013) Am J Transplant , vol.13 , pp. 663-675
    • Le Quintrec, M.1
  • 64
    • 34548400755 scopus 로고    scopus 로고
    • Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: Prognostic significance of genetic background
    • Bresin E et al. Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background. Clin J Am Soc Nephrol 2006;1:88-99
    • (2006) Clin J Am Soc Nephrol , vol.1 , pp. 88-99
    • Bresin, E.1
  • 65
    • 84887024143 scopus 로고    scopus 로고
    • Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation
    • Noris M, Remuzzi G. Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation. Curr Opin Nephrol Hypertens 2013;22:704-712
    • (2013) Curr Opin Nephrol Hypertens , vol.22 , pp. 704-712
    • Noris, M.1    Remuzzi, G.2
  • 66
    • 48349086641 scopus 로고    scopus 로고
    • Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation
    • Le Quintrec M et al. Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation. Am J Transplant 2008;8:1694-1701
    • (2008) Am J Transplant , vol.8 , pp. 1694-1701
    • Le Quintrec, M.1
  • 67
    • 84902139084 scopus 로고    scopus 로고
    • Eculizumab for drug-induced de novo posttransplantation thrombotic microangiopathy: A case report
    • Safa K et al. Eculizumab for drug-induced de novo posttransplantation thrombotic microangiopathy: A case report. Clin Nephrol 2015;83:125-129
    • (2015) Clin Nephrol , vol.83 , pp. 125-129
    • Safa, K.1
  • 68
    • 84976534215 scopus 로고    scopus 로고
    • Two cases of kidney transplantation-associated thrombotic microangiopathy successfully treated with eculizumab
    • Ikeda T et al. Two cases of kidney transplantation-associated thrombotic microangiopathy successfully treated with eculizumab. Nephrology (Carlton) 2016;21:35-40
    • (2016) Nephrology (Carlton) , vol.21 , pp. 35-40
    • Ikeda, T.1
  • 69
    • 84979067029 scopus 로고    scopus 로고
    • Late onset of de novo atypical hemolytic-uremic syndrome presented on a simultaneous pancreas and kidney transplant recipient successfully treated with eculizumab
    • Juega-Marino FJ et al. Late onset of de novo atypical hemolytic-uremic syndrome presented on a simultaneous pancreas and kidney transplant recipient successfully treated with eculizumab. Nefrologia 2016;36:328-329
    • (2016) Nefrologia , vol.36 , pp. 328-329
    • Juega-Marino, F.J.1
  • 70
    • 80054767700 scopus 로고    scopus 로고
    • Successful treatment of de novo posttransplant thrombotic microangiopathy with eculizumab
    • Wilson CH et al. Successful treatment of de novo posttransplant thrombotic microangiopathy with eculizumab. Transplantation 2011;92:e42-e43
    • (2011) Transplantation , vol.92 , pp. e42-e43
    • Wilson, C.H.1
  • 71
    • 79959390955 scopus 로고    scopus 로고
    • Eculizumab for the treatment of de novo thrombotic microangiopathy post simultaneous pancreaskidney transplantation-a case report
    • Chandran S et al. Eculizumab for the treatment of de novo thrombotic microangiopathy post simultaneous pancreaskidney transplantation-a case report. Transplant Proc 2011;43:2097-2101
    • (2011) Transplant Proc , vol.43 , pp. 2097-2101
    • Chandran, S.1
  • 72
    • 0141781175 scopus 로고    scopus 로고
    • Outcome of plasma exchange therapy in thrombotic microangiopathy after renal transplantation
    • Karthikeyan V et al. Outcome of plasma exchange therapy in thrombotic microangiopathy after renal transplantation. Am J Transplant 2003;3:1289-1294
    • (2003) Am J Transplant , vol.3 , pp. 1289-1294
    • Karthikeyan, V.1
  • 73
    • 85030392725 scopus 로고    scopus 로고
    • Use of belatacept as alternative immunosuppression in three renal transplant patients with de novo drug-induced thrombotic microangiopathy
    • Cicora F et al. Use of belatacept as alternative immunosuppression in three renal transplant patients with de novo drug-induced thrombotic microangiopathy. Case Rep Med 2013;2013:260254
    • (2013) Case Rep Med , vol.2013 , pp. 260254
    • Cicora, F.1
  • 74
    • 84923673542 scopus 로고    scopus 로고
    • De novo tacrolimus-induced thrombotic microangiopathy in the early stage after renal transplantation successfully treated with conversion to everolimus
    • Cortina G et al. De novo tacrolimus-induced thrombotic microangiopathy in the early stage after renal transplantation successfully treated with conversion to everolimus. Pediatr Nephrol 2015;30:693-697
    • (2015) Pediatr Nephrol , vol.30 , pp. 693-697
    • Cortina, G.1
  • 75
    • 41049113480 scopus 로고    scopus 로고
    • Thrombotic microangiopathy following pancreas after kidney transplants
    • Lipshutz GS et al. Thrombotic microangiopathy following pancreas after kidney transplants. Clin Transplant 2008;22:236-241
    • (2008) Clin Transplant , vol.22 , pp. 236-241
    • Lipshutz, G.S.1
  • 76
    • 84867983968 scopus 로고    scopus 로고
    • The role of complement in antibody-mediated rejection in kidney transplantation
    • Stegall MD, Chedid MF, Cornell LD. The role of complement in antibody-mediated rejection in kidney transplantation. Nat Rev Nephrol 2012;8:670-678
    • (2012) Nat Rev Nephrol , vol.8 , pp. 670-678
    • Stegall, M.D.1    Chedid, M.F.2    Cornell, L.D.3
  • 77
    • 84865611225 scopus 로고    scopus 로고
    • Antibody mediated rejection associated with complement factor h-related protein 3/1 deficiency successfully treated with eculizumab
    • Noone D et al. Antibody mediated rejection associated with complement factor h-related protein 3/1 deficiency successfully treated with eculizumab. Am J Transplant 2012;12:2546-2553
    • (2012) Am J Transplant , vol.12 , pp. 2546-2553
    • Noone, D.1
  • 78
    • 85016793639 scopus 로고    scopus 로고
    • Eculizumab for the treatment of severe antibody-mediated rejection: A case report and review of the literature
    • Tran D et al. Eculizumab for the treatment of severe antibody-mediated rejection: a case report and review of the literature. Case Rep Transplant 2016;2016:9874261
    • (2016) Case Rep Transplant , vol.2016 , pp. 9874261
    • Tran, D.1
  • 79
    • 84869038452 scopus 로고    scopus 로고
    • Eculizumab treatment of acute antibody-mediated rejection in renal transplantation: Case reports
    • Gonzalez-Roncero F et al. Eculizumab treatment of acute antibody-mediated rejection in renal transplantation: case reports. Transplant Proc 2012;44:2690-2694
    • (2012) Transplant Proc , vol.44 , pp. 2690-2694
    • Gonzalez-Roncero, F.1
  • 80
    • 84870244762 scopus 로고    scopus 로고
    • Case report: Eculizumab rescue of severe accelerated antibody-mediated rejection after ABO-incompatible kidney transplant
    • Stewart ZA et al. Case report: eculizumab rescue of severe accelerated antibody-mediated rejection after ABO-incompatible kidney transplant. Transplant Proc 2012;44:3033-3036
    • (2012) Transplant Proc , vol.44 , pp. 3033-3036
    • Stewart, Z.A.1
  • 81
    • 84555210096 scopus 로고    scopus 로고
    • Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients
    • Stegall MD et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011;11:2405-2413
    • (2011) Am J Transplant , vol.11 , pp. 2405-2413
    • Stegall, M.D.1
  • 82
    • 84928089457 scopus 로고    scopus 로고
    • Positive crossmatch kidney transplant recipients treated with eculizumab: Outcomes beyond 1 year
    • Cornell LD et al. Positive crossmatch kidney transplant recipients treated with eculizumab: outcomes beyond 1 year. Am J Transplant 2015;15:1293-1302
    • (2015) Am J Transplant , vol.15 , pp. 1293-1302
    • Cornell, L.D.1
  • 83
    • 85014072324 scopus 로고    scopus 로고
    • Eculizumab therapy for chronic antibodymediated injury in kidney transplant recipients: A pilot randomized controlled trial
    • Kulkarni S et al. Eculizumab therapy for chronic antibodymediated injury in kidney transplant recipients: a pilot randomized controlled trial. Am J Transplant 2016
    • (2016) Am J Transplant
    • Kulkarni, S.1
  • 84
    • 84891825219 scopus 로고    scopus 로고
    • Plasmapheresis-resistant acute humoral rejection successfully treated with anti-C5 antibody
    • Ghirardo G et al. Plasmapheresis-resistant acute humoral rejection successfully treated with anti-C5 antibody. Pediatr Transplant 2014;18:E1-E5
    • (2014) Pediatr Transplant , vol.18 , pp. E1-E5
    • Ghirardo, G.1
  • 85
    • 58049206825 scopus 로고    scopus 로고
    • The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection
    • Locke JE et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant 2009;9:231-235
    • (2009) Am J Transplant , vol.9 , pp. 231-235
    • Locke, J.E.1
  • 86
    • 84922658935 scopus 로고    scopus 로고
    • Eculizumab to treat antibody-mediated rejection in a 7-year-old kidney transplant recipient
    • Chehade H et al. Eculizumab to treat antibody-mediated rejection in a 7-year-old kidney transplant recipient. Pediatrics 2015;135:e551-e555
    • (2015) Pediatrics , vol.135 , pp. e551-e555
    • Chehade, H.1
  • 87
    • 79960120521 scopus 로고    scopus 로고
    • Prompt reversal of a severe complement activation by eculizumab in a patient undergoing intentional ABO-incompatible pancreas and kidney transplantation
    • Biglarnia AR et al. Prompt reversal of a severe complement activation by eculizumab in a patient undergoing intentional ABO-incompatible pancreas and kidney transplantation. Transpl Int 2011;24:e61-e66
    • (2011) Transpl Int , vol.24 , pp. e61-e66
    • Biglarnia, A.R.1
  • 88
    • 84927798214 scopus 로고    scopus 로고
    • Report of the inefficacy of eculizumab in two cases of severe antibody-mediated rejection of renal grafts
    • Burbach M et al. Report of the inefficacy of eculizumab in two cases of severe antibody-mediated rejection of renal grafts. Transplantation 2014;98:1056-1059
    • (2014) Transplantation , vol.98 , pp. 1056-1059
    • Burbach, M.1
  • 89
    • 84922014185 scopus 로고    scopus 로고
    • Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection after HLA-incompatible kidney transplantation
    • Orandi BJ et al. Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection after HLA-incompatible kidney transplantation. Transplantation 2014;98:857-863
    • (2014) Transplantation , vol.98 , pp. 857-863
    • Orandi, B.J.1
  • 90
    • 84911129829 scopus 로고    scopus 로고
    • Antibody-mediated rejection despite inhibition of terminal complement
    • Bentall A et al. Antibody-mediated rejection despite inhibition of terminal complement. Transpl Int 2014;27:1235-1243
    • (2014) Transpl Int , vol.27 , pp. 1235-1243
    • Bentall, A.1
  • 91
    • 84939456967 scopus 로고    scopus 로고
    • Eculizumab for treatment of refractory antibody-mediated rejection in kidney transplant patients: A single-center experience
    • Yelken B et al. Eculizumab for treatment of refractory antibody-mediated rejection in kidney transplant patients: a single-center experience. Transplant Proc 2015;47:1754-1759
    • (2015) Transplant Proc , vol.47 , pp. 1754-1759
    • Yelken, B.1
  • 92
    • 74949094555 scopus 로고    scopus 로고
    • KDIGO clinical practice guideline for the care of kidney transplant recipients
    • Kidney Disease: Improving Global Outcomes Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009;9:S1-S155
    • (2009) Am J Transplant , vol.9 , pp. S1-S155
  • 93
    • 84922349792 scopus 로고    scopus 로고
    • Loss of DGKepsilon induces endothelial cell activation and death independently of complement activation
    • Bruneau S et al. Loss of DGKepsilon induces endothelial cell activation and death independently of complement activation. Blood 2015;125:1038-1046
    • (2015) Blood , vol.125 , pp. 1038-1046
    • Bruneau, S.1
  • 94
    • 84878608990 scopus 로고    scopus 로고
    • Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome
    • Lemaire M et al. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet 2013;45:531-536
    • (2013) Nat Genet , vol.45 , pp. 531-536
    • Lemaire, M.1
  • 95
    • 84908170447 scopus 로고    scopus 로고
    • Complement mutations in diacylglycerol kinase-epsilon-associated atypical hemolytic uremic syndrome
    • Sanchez Chinchilla D et al. Complement mutations in diacylglycerol kinase-epsilon-associated atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2014;9:1611-1619
    • (2014) Clin J Am Soc Nephrol , vol.9 , pp. 1611-1619
    • Sanchez Chinchilla, D.1
  • 96
    • 84930441272 scopus 로고    scopus 로고
    • Characterization of a new DGKE intronic mutation in genetically unsolved cases of familial atypical hemolytic uremic syndrome
    • Mele C et al. Characterization of a new DGKE intronic mutation in genetically unsolved cases of familial atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2015;10:1011-1019
    • (2015) Clin J Am Soc Nephrol , vol.10 , pp. 1011-1019
    • Mele, C.1
  • 97
    • 84902135216 scopus 로고    scopus 로고
    • Phenotypic expansion of DGKE-associated diseases
    • Westland R et al. Phenotypic expansion of DGKE-associated diseases. J Am Soc Nephrol 2014;25:1408-1414
    • (2014) J Am Soc Nephrol , vol.25 , pp. 1408-1414
    • Westland, R.1
  • 98
    • 84883420511 scopus 로고    scopus 로고
    • Complement activation associated with ADAMTS13 deficiency in human and murine thrombotic microangiopathy
    • Tati R et al. Complement activation associated with ADAMTS13 deficiency in human and murine thrombotic microangiopathy. J Immunol 2013;191:2184-2193
    • (2013) J Immunol , vol.191 , pp. 2184-2193
    • Tati, R.1
  • 99
    • 20144365269 scopus 로고    scopus 로고
    • Complement activation: The missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies
    • Ruiz-Torres MP et al. Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies. Thromb Haemost 2005;93:443-452
    • (2005) Thromb Haemost , vol.93 , pp. 443-452
    • Ruiz-Torres, M.P.1
  • 100
    • 84994607433 scopus 로고    scopus 로고
    • Human neutrophil peptides and complement factor Bb in pathogenesis of acquired thrombotic thrombocytopenic purpura
    • Cao W et al. Human neutrophil peptides and complement factor Bb in pathogenesis of acquired thrombotic thrombocytopenic purpura. Haematologica 2016;101:1319-1326
    • (2016) Haematologica , vol.101 , pp. 1319-1326
    • Cao, W.1
  • 101
    • 84860474599 scopus 로고    scopus 로고
    • Complement activation in thrombotic thrombocytopenic purpura
    • Reti M et al. Complement activation in thrombotic thrombocytopenic purpura. J Thromb Haemost 2012;10:791-798
    • (2012) J Thromb Haemost , vol.10 , pp. 791-798
    • Reti, M.1
  • 102
    • 84894705729 scopus 로고    scopus 로고
    • Complement and cytokine response in acute Thrombotic Thrombocytopenic Purpura
    • Westwood JP et al. Complement and cytokine response in acute Thrombotic Thrombocytopenic Purpura. Br J Haematol 2014;164:858-866
    • (2014) Br J Haematol , vol.164 , pp. 858-866
    • Westwood, J.P.1
  • 103
    • 84885339216 scopus 로고    scopus 로고
    • Complement activation and mortality during an acute episode of thrombotic thrombocytopenic purpura
    • Wu TC et al. Complement activation and mortality during an acute episode of thrombotic thrombocytopenic purpura. J Thromb Haemost 2013;11:1925-1927
    • (2013) J Thromb Haemost , vol.11 , pp. 1925-1927
    • Wu, T.C.1
  • 104
    • 84959575823 scopus 로고    scopus 로고
    • Genetic variations in complement factors in patients with congenital thrombotic thrombocytopenic purpura with renal insufficiency
    • Fan X et al. Genetic variations in complement factors in patients with congenital thrombotic thrombocytopenic purpura with renal insufficiency. Int J Hematol 2016;103:283-291
    • (2016) Int J Hematol , vol.103 , pp. 283-291
    • Fan, X.1
  • 105
    • 23944468642 scopus 로고    scopus 로고
    • Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement
    • Noris M et al. Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement. J Am Soc Nephrol 2005;16:1177-1183
    • (2005) J Am Soc Nephrol , vol.16 , pp. 1177-1183
    • Noris, M.1
  • 106
    • 84861526957 scopus 로고    scopus 로고
    • Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura
    • Chapin J et al. Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura. Br J Haematol 2012;157:772-774
    • (2012) Br J Haematol , vol.157 , pp. 772-774
    • Chapin, J.1
  • 107
    • 84880700770 scopus 로고    scopus 로고
    • Use of eculizumab in the treatment of a case of refractory, ADAMTS13-deficient thrombotic thrombocytopenic purpura: Additional data and clinical follow-up
    • Tsai E et al. Use of eculizumab in the treatment of a case of refractory, ADAMTS13-deficient thrombotic thrombocytopenic purpura: additional data and clinical follow-up. Br J Haematol 2013;162:558-559
    • (2013) Br J Haematol , vol.162 , pp. 558-559
    • Tsai, E.1
  • 108
    • 84948085489 scopus 로고    scopus 로고
    • Treatment of congenital thrombotic thrombocytopenic purpura with eculizumab
    • Pecoraro C et al. Treatment of congenital thrombotic thrombocytopenic purpura with eculizumab. Am J Kidney Dis 2015;66:1067-1070
    • (2015) Am J Kidney Dis , vol.66 , pp. 1067-1070
    • Pecoraro, C.1
  • 109
    • 84975795988 scopus 로고    scopus 로고
    • Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: The seventh special issue
    • Schwartz J et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the seventh special issue. J Clin Apher 2016;31:149-162
    • (2016) J Clin Apher , vol.31 , pp. 149-162
    • Schwartz, J.1
  • 110
    • 80051866867 scopus 로고    scopus 로고
    • A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura
    • Scully M et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood 2011;118:1746-1753
    • (2011) Blood , vol.118 , pp. 1746-1753
    • Scully, M.1
  • 111
    • 84934434760 scopus 로고    scopus 로고
    • A phase-II sequential case-series study of all patients presenting to four plasma exchange centres with presumed relapsed/refractory thrombotic thrombocytopenic purpura treated with rituximab
    • Clark WF et al. A phase-II sequential case-series study of all patients presenting to four plasma exchange centres with presumed relapsed/refractory thrombotic thrombocytopenic purpura treated with rituximab. Br J Haematol 2015;170:208-217
    • (2015) Br J Haematol , vol.170 , pp. 208-217
    • Clark, W.F.1
  • 112
    • 84995581864 scopus 로고    scopus 로고
    • Efficacy of a rituximab regimen based on B cell depletion in thrombotic thrombocytopenic purpura with suboptimal response to standard treatment: Results of a phase II, multicenter non-comparative study
    • Benhamou Y et al. Efficacy of a rituximab regimen based on B cell depletion in thrombotic thrombocytopenic purpura with suboptimal response to standard treatment: Results of a phase II, multicenter non-comparative study. Am J Hematol 2016
    • (2016) Am J Hematol
    • Benhamou, Y.1
  • 113
    • 84959293895 scopus 로고    scopus 로고
    • Caplacizumab for acquired thrombotic thrombocytopenic purpura
    • Peyvandi F et al. Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med 2016;374:511-522
    • (2016) N Engl J Med , vol.374 , pp. 511-522
    • Peyvandi, F.1
  • 114
    • 77952556624 scopus 로고    scopus 로고
    • Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations
    • Fakhouri F et al. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol 2010;21:859-67
    • (2010) J Am Soc Nephrol , vol.21 , pp. 859-867
    • Fakhouri, F.1
  • 115
    • 84880958391 scopus 로고    scopus 로고
    • Eculizumab for atypical hemolytic uremic syndrome in pregnancy
    • Ardissino G et al. Eculizumab for atypical hemolytic uremic syndrome in pregnancy. Obstet Gynecol 2013;122(2 Pt 2):487-489
    • (2013) Obstet Gynecol , vol.122 , Issue.2 , pp. 487-489
    • Ardissino, G.1
  • 116
    • 84879576278 scopus 로고    scopus 로고
    • Successful treatment of the postpartum atypical hemolytic uremic syndrome with eculizumab
    • Zschiedrich S, Prager EP, Kuehn EW. Successful treatment of the postpartum atypical hemolytic uremic syndrome with eculizumab. Ann Intern Med 2013;159:176
    • (2013) Ann Intern Med , vol.159 , pp. 176
    • Zschiedrich, S.1    Prager, E.P.2    Kuehn, E.W.3
  • 117
    • 84904095940 scopus 로고    scopus 로고
    • Thrombotic thrombocytopenic purpura and pregnancy: Presentation, management, and subsequent pregnancy outcomes
    • Scully M et al. Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes. Blood 2014;124:211-219
    • (2014) Blood , vol.124 , pp. 211-219
    • Scully, M.1
  • 118
    • 84963600144 scopus 로고    scopus 로고
    • Direct evidence of complement activation in HELLP syndrome: A link to atypical hemolytic uremic syndrome
    • Vaught AJ et al. Direct evidence of complement activation in HELLP syndrome: A link to atypical hemolytic uremic syndrome. Exp Hematol 2016;44:390-398
    • (2016) Exp Hematol , vol.44 , pp. 390-398
    • Vaught, A.J.1
  • 119
    • 0025113399 scopus 로고
    • Enhanced anaphylatoxin and terminal C5b-9 complement complex formation in patients with the syndrome of hemolysis, elevated liver enzymes, and low platelet count
    • Haeger M, Unander M, Bengtsson A. Enhanced anaphylatoxin and terminal C5b-9 complement complex formation in patients with the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet Gynecol 1990;76:698-702
    • (1990) Obstet Gynecol , vol.76 , pp. 698-702
    • Haeger, M.1    Unander, M.2    Bengtsson, A.3
  • 120
    • 77950628595 scopus 로고    scopus 로고
    • Activation of the complement system in normal pregnancy and preeclampsia
    • Derzsy Z et al. Activation of the complement system in normal pregnancy and preeclampsia. Mol Immunol 2010;47:1500-1506
    • (2010) Mol Immunol , vol.47 , pp. 1500-1506
    • Derzsy, Z.1
  • 121
    • 84982141403 scopus 로고    scopus 로고
    • Expression of the complement system's activation factors in plasma of patients with early/late-onset severe pre-eclampsia
    • He Y et al. Expression of the complement system's activation factors in plasma of patients with early/late-onset severe pre-eclampsia. Am J Reprod Immunol 2016;76:205-211
    • (2016) Am J Reprod Immunol , vol.76 , pp. 205-211
    • He, Y.1
  • 122
    • 70349978795 scopus 로고    scopus 로고
    • Human serum complement C3 and factor H in the syndrome of hemolysis, elevated liver enzymes, and low platelet count
    • Ari E et al. Human serum complement C3 and factor H in the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Am J Reprod Immunol 2009;62:238-242
    • (2009) Am J Reprod Immunol , vol.62 , pp. 238-242
    • Ari, E.1
  • 123
    • 57649241639 scopus 로고    scopus 로고
    • Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome
    • Fakhouri F et al. Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome. Blood 2008;112:4542-4545
    • (2008) Blood , vol.112 , pp. 4542-4545
    • Fakhouri, F.1
  • 124
    • 84867566240 scopus 로고    scopus 로고
    • The genetics of the alternative pathway of complement in the pathogenesis of HELLP syndrome
    • Crovetto F et al. The genetics of the alternative pathway of complement in the pathogenesis of HELLP syndrome. J Matern Fetal Neonatal Med 2012;25:2322-2325
    • (2012) J Matern Fetal Neonatal Med , vol.25 , pp. 2322-2325
    • Crovetto, F.1
  • 125
    • 79953691827 scopus 로고    scopus 로고
    • Mutations in complement regulatory proteins predispose to preeclampsia: A genetic analysis of the PROMISSE cohort
    • Salmon JE et al. Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort. PLoS Med 2011;8:e1001013
    • (2011) PLoS Med , vol.8 , pp. e1001013
    • Salmon, J.E.1
  • 126
    • 84941276223 scopus 로고    scopus 로고
    • Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria
    • Kelly RJ et al. Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2015;373:1032-1039
    • (2015) N Engl J Med , vol.373 , pp. 1032-1039
    • Kelly, R.J.1
  • 127
    • 85026919072 scopus 로고    scopus 로고
    • Atypical haemolytic uraemic syndrome and pregnancy: Outcome with ongoing eculizumab
    • Servais A et al. Atypical haemolytic uraemic syndrome and pregnancy: outcome with ongoing eculizumab. Nephrol Dial Transplant 2016
    • (2016) Nephrol Dial Transplant
    • Servais, A.1
  • 128
    • 84873288473 scopus 로고    scopus 로고
    • Eculizumab for the treatment of preeclampsia/HELLP syndrome
    • Burwick RM, Feinberg BB. Eculizumab for the treatment of preeclampsia/HELLP syndrome. Placenta 2013;34:201-203
    • (2013) Placenta , vol.34 , pp. 201-203
    • Burwick, R.M.1    Feinberg, B.B.2
  • 129
    • 85030442306 scopus 로고    scopus 로고
    • Renal thrombotic microangiopathy in patients with cblC defect: Review of an under-recognized entity
    • Beck BB et al. Renal thrombotic microangiopathy in patients with cblC defect: review of an under-recognized entity. Pediatr Nephrol 2016
    • (2016) Pediatr Nephrol
    • Beck, B.B.1
  • 130
    • 78449267023 scopus 로고    scopus 로고
    • CD46-associated atypical hemolytic uremic syndrome with uncommon course caused by cblC deficiency
    • Bouts AH et al. CD46-associated atypical hemolytic uremic syndrome with uncommon course caused by cblC deficiency. Pediatr Nephrol 2010;25:2547-2548
    • (2010) Pediatr Nephrol , vol.25 , pp. 2547-2548
    • Bouts, A.H.1
  • 131
    • 14844321537 scopus 로고    scopus 로고
    • Late-onset thrombocytic microangiopathy caused by cblC disease: Association with a factor H mutation
    • Guigonis V et al. Late-onset thrombocytic microangiopathy caused by cblC disease: association with a factor H mutation. Am J Kidney Dis 2005;45:588-595
    • (2005) Am J Kidney Dis , vol.45 , pp. 588-595
    • Guigonis, V.1
  • 132
    • 84896514393 scopus 로고    scopus 로고
    • Adult-onset eculizumab-resistant hemolytic uremic syndrome associated with cobalamin C deficiency
    • Cornec-Le Gall E et al. Adult-onset eculizumab-resistant hemolytic uremic syndrome associated with cobalamin C deficiency. Am J Kidney Dis 2014;63:119-123
    • (2014) Am J Kidney Dis , vol.63 , pp. 119-123
    • Cornec-Le Gall, E.1
  • 133
    • 79960435714 scopus 로고    scopus 로고
    • Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis
    • Morigi M et al. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J Immunol 2011;187:172-180
    • (2011) J Immunol , vol.187 , pp. 172-180
    • Morigi, M.1
  • 134
    • 85003678427 scopus 로고    scopus 로고
    • Human mannose-binding lectin inhibitor prevents Shiga toxin-induced renal injury
    • Ozaki M et al. Human mannose-binding lectin inhibitor prevents Shiga toxin-induced renal injury. Kidney Int 2016;90:774-782
    • (2016) Kidney Int , vol.90 , pp. 774-782
    • Ozaki, M.1
  • 135
    • 84912520417 scopus 로고    scopus 로고
    • Shiga toxin promotes podocyte injury in experimental hemolytic uremic syndrome via activation of the alternative pathway of complement
    • Locatelli M et al. Shiga toxin promotes podocyte injury in experimental hemolytic uremic syndrome via activation of the alternative pathway of complement. J Am Soc Nephrol 2014;25:1786-1798
    • (2014) J Am Soc Nephrol , vol.25 , pp. 1786-1798
    • Locatelli, M.1
  • 136
    • 70350693665 scopus 로고    scopus 로고
    • Shiga toxin activates complement and binds factor H: Evidence for an active role of complement in hemolytic uremic syndrome
    • Orth D et al. Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome. J Immunol 2009;182:6394-6400
    • (2009) J Immunol , vol.182 , pp. 6394-6400
    • Orth, D.1
  • 137
    • 84889579190 scopus 로고    scopus 로고
    • Interaction of Shiga toxin 2 with complement regulators of the factor H protein family
    • Poolpol K et al. Interaction of Shiga toxin 2 with complement regulators of the factor H protein family. Mol Immunol 2014;58:77-84
    • (2014) Mol Immunol , vol.58 , pp. 77-84
    • Poolpol, K.1
  • 138
    • 79956293593 scopus 로고    scopus 로고
    • Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome
    • Stahl AL, Sartz L, Karpman D. Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Blood 2011;117:5503-5513
    • (2011) Blood , vol.117 , pp. 5503-5513
    • Stahl, A.L.1    Sartz, L.2    Karpman, D.3
  • 139
    • 84924358744 scopus 로고    scopus 로고
    • Shiga toxin-induced complement-mediated hemolysis and release of complement-coated red blood cell-derived microvesicles in hemolytic uremic syndrome
    • Arvidsson I et al. Shiga toxin-induced complement-mediated hemolysis and release of complement-coated red blood cell-derived microvesicles in hemolytic uremic syndrome. JImmunol 2015;194:2309-2318
    • (2015) JImmunol , vol.194 , pp. 2309-2318
    • Arvidsson, I.1
  • 140
    • 85007367202 scopus 로고    scopus 로고
    • Systemic complement activation and complement gene analysis in enterohaemorrhagic Escherichia coli-associated paediatric haemolytic uraemic syndrome
    • Ahlenstiel-Grunow T et al. Systemic complement activation and complement gene analysis in enterohaemorrhagic Escherichia coli-associated paediatric haemolytic uraemic syndrome. Nephrol Dial Transplant 2016;31:1114-1121
    • (2016) Nephrol Dial Transplant , vol.31 , pp. 1114-1121
    • Ahlenstiel-Grunow, T.1
  • 141
    • 84930415185 scopus 로고    scopus 로고
    • Activation of the alternative pathway of complement during the acute phase of typical haemolytic uraemic syndrome
    • Ferraris JR et al. Activation of the alternative pathway of complement during the acute phase of typical haemolytic uraemic syndrome. Clin Exp Immunol 2015;181:118-125
    • (2015) Clin Exp Immunol , vol.181 , pp. 118-125
    • Ferraris, J.R.1
  • 142
    • 73649122762 scopus 로고    scopus 로고
    • Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome
    • Thurman JM et al. Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 2009;4:1920-1924
    • (2009) Clin J Am Soc Nephrol , vol.4 , pp. 1920-1924
    • Thurman, J.M.1
  • 143
    • 84881374227 scopus 로고    scopus 로고
    • Two patients with history of STEC-HUS, posttransplant recurrence and complement gene mutations
    • Alberti M et al. Two patients with history of STEC-HUS, posttransplant recurrence and complement gene mutations. Am J Transplant 2013;13:2201-2206
    • (2013) Am J Transplant , vol.13 , pp. 2201-2206
    • Alberti, M.1
  • 144
    • 84947485143 scopus 로고    scopus 로고
    • CFH gene mutation in a case of Shiga toxinassociated hemolytic uremic syndrome (STEC-HUS)
    • Caillaud C et al. CFH gene mutation in a case of Shiga toxinassociated hemolytic uremic syndrome (STEC-HUS). Pediatr Nephrol 2016;31:157-161
    • (2016) Pediatr Nephrol , vol.31 , pp. 157-161
    • Caillaud, C.1
  • 145
    • 85013016536 scopus 로고    scopus 로고
    • A de novo deletion in the regulators of complement activation cluster producing a hybrid complement factor H/complement factor H-related 3 gene in atypical hemolytic uremic syndrome
    • Challis RC et al. A de novo deletion in the regulators of complement activation cluster producing a hybrid complement factor H/complement factor H-related 3 gene in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2016;27:1617-1624
    • (2016) J Am Soc Nephrol , vol.27 , pp. 1617-1624
    • Challis, R.C.1
  • 146
    • 85037989595 scopus 로고    scopus 로고
    • Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome
    • Westra D et al. Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome. Pediatr Nephrol 2016
    • (2016) Pediatr Nephrol
    • Westra, D.1
  • 147
    • 84868562798 scopus 로고    scopus 로고
    • Best supportive care and therapeutic plasma exchange with or without eculizumab in Shigatoxin-producing E. Coli O104:H4 induced haemolyticuraemic syndrome: An analysis of the German STEC-HUS registry
    • Kielstein JT et al. Best supportive care and therapeutic plasma exchange with or without eculizumab in Shigatoxin-producing E. coli O104:H4 induced haemolyticuraemic syndrome: an analysis of the German STEC-HUS registry. Nephrol Dial Transplant 2012;27:3807-3815
    • (2012) Nephrol Dial Transplant , vol.27 , pp. 3807-3815
    • Kielstein, J.T.1
  • 148
    • 84864876679 scopus 로고    scopus 로고
    • Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: Case-control study
    • Menne J et al. Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ 2012;345:e4565
    • (2012) BMJ , vol.345 , pp. e4565
    • Menne, J.1
  • 149
    • 79959776422 scopus 로고    scopus 로고
    • Eculizumab in severe Shiga-toxinassociated HUS
    • Lapeyraque AL et al. Eculizumab in severe Shiga-toxinassociated HUS. NEngl J Med 2011;364:2561-2563
    • (2011) NEngl J Med , vol.364 , pp. 2561-2563
    • Lapeyraque, A.L.1
  • 150
    • 84885953550 scopus 로고    scopus 로고
    • Long-term outcomes of Shiga toxin hemolytic uremic syndrome
    • Spinale JM et al. Long-term outcomes of Shiga toxin hemolytic uremic syndrome. Pediatr Nephrol 2013;28:2097-2105
    • (2013) Pediatr Nephrol , vol.28 , pp. 2097-2105
    • Spinale, J.M.1
  • 151
    • 80053246996 scopus 로고    scopus 로고
    • Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4-associated haemolytic uraemic syndrome: A prospective trial
    • Greinacher A et al. Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4-associated haemolytic uraemic syndrome: a prospective trial. Lancet 2011;378:1166-1173
    • (2011) Lancet , vol.378 , pp. 1166-1173
    • Greinacher, A.1
  • 152
    • 58249107186 scopus 로고    scopus 로고
    • Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: A systematic review of randomized controlled trials
    • Michael M et al. Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials. Am J Kidney Dis 2009;53:259-272
    • (2009) Am J Kidney Dis , vol.53 , pp. 259-272
    • Michael, M.1
  • 153
    • 84865491675 scopus 로고    scopus 로고
    • An outbreak of Shiga toxin-producing Escherichia coli O104:H4 hemolytic uremic syndrome in Germany: Presentation and short-term outcome in children
    • Loos S et al. An outbreak of Shiga toxin-producing Escherichia coli O104:H4 hemolytic uremic syndrome in Germany: presentation and short-term outcome in children. Clin Infect Dis 2012;55:753-759
    • (2012) Clin Infect Dis , vol.55 , pp. 753-759
    • Loos, S.1
  • 154
    • 27944505853 scopus 로고    scopus 로고
    • In vivo binding of complement regulator factor H by Streptococcus pneumoniae
    • Quin LR et al. In vivo binding of complement regulator factor H by Streptococcus pneumoniae. J Infect Dis 2005;192:1996-2003
    • (2005) J Infect Dis , vol.192 , pp. 1996-2003
    • Quin, L.R.1
  • 155
    • 84855256386 scopus 로고    scopus 로고
    • Is complement a culprit in infectioninduced forms of haemolytic uraemic syndrome?
    • Johnson S, Waters A. Is complement a culprit in infectioninduced forms of haemolytic uraemic syndrome? Immunobiology 2012;217:235-243
    • (2012) Immunobiology , vol.217 , pp. 235-243
    • Johnson, S.1    Waters, A.2
  • 156
    • 84881555729 scopus 로고    scopus 로고
    • Does dysregulated complement activation contribute to haemolytic uraemic syndrome secondary to Streptococcus pneumoniae?
    • Gilbert RD, Nagra A, Haq MR. Does dysregulated complement activation contribute to haemolytic uraemic syndrome secondary to Streptococcus pneumoniae? Med Hypotheses 2013;81:400-403
    • (2013) Med Hypotheses , vol.81 , pp. 400-403
    • Gilbert, R.D.1    Nagra, A.2    Haq, M.R.3
  • 157
    • 84884526601 scopus 로고    scopus 로고
    • The role of complement in Streptococcus pneumoniae-associated haemolytic uraemic syndrome
    • Szilagyi A et al. The role of complement in Streptococcus pneumoniae-associated haemolytic uraemic syndrome. Nephrol Dial Transplant 2013;28:2237-2245
    • (2013) Nephrol Dial Transplant , vol.28 , pp. 2237-2245
    • Szilagyi, A.1
  • 159
    • 84992088843 scopus 로고    scopus 로고
    • Thrombotic microangiopathy and human immunodeficiency virus in the era of eculizumab
    • Jin A et al. Thrombotic microangiopathy and human immunodeficiency virus in the era of eculizumab. Clin Kidney J 2016;9:576-579
    • (2016) Clin Kidney J , vol.9 , pp. 576-579
    • Jin, A.1
  • 160
    • 0037213442 scopus 로고    scopus 로고
    • Light at the end of the TUNEL: HIV-associated thrombotic microangiopathy
    • Alpers CE. Light at the end of the TUNEL: HIV-associated thrombotic microangiopathy. Kidney Int 2003;63:385-396
    • (2003) Kidney Int , vol.63 , pp. 385-396
    • Alpers, C.E.1
  • 161
    • 0033016111 scopus 로고    scopus 로고
    • Acute renal failure in the course of HIV infection: A single-institution retrospective study of ninetytwo patients and sixty renal biopsies
    • Peraldi MN et al. Acute renal failure in the course of HIV infection: a single-institution retrospective study of ninetytwo patients and sixty renal biopsies. Nephrol Dial Transplant 1999;14:1578-1585
    • (1999) Nephrol Dial Transplant , vol.14 , pp. 1578-1585
    • Peraldi, M.N.1
  • 162
    • 7444246754 scopus 로고    scopus 로고
    • HIV-associated thrombotic microangiopathy in the era of highly active antiretroviral therapy: An observational study
    • Becker S et al. HIV-associated thrombotic microangiopathy in the era of highly active antiretroviral therapy: an observational study. Clin Infect Dis 2004;39:S267-S275
    • (2004) Clin Infect Dis , vol.39 , pp. S267-S275
    • Becker, S.1
  • 163
    • 84938743746 scopus 로고    scopus 로고
    • Cytomegalovirus-induced thrombotic microangiopathy after renal transplant successfully treated with eculizumab: Case report and review of the literature
    • Java A et al. Cytomegalovirus-induced thrombotic microangiopathy after renal transplant successfully treated with eculizumab: case report and review of the literature. Transpl Int 2015;28:1121-1125
    • (2015) Transpl Int , vol.28 , pp. 1121-1125
    • Java, A.1
  • 164
    • 84856713252 scopus 로고    scopus 로고
    • Conditioning for hematopoietic transplantation activates the complement cascade and induces a proteolytic environment in bone marrow: A novel role for bioactive lipids and soluble C5b-C9 as homing factors
    • Kim CH et al. Conditioning for hematopoietic transplantation activates the complement cascade and induces a proteolytic environment in bone marrow: a novel role for bioactive lipids and soluble C5b-C9 as homing factors. Leukemia 2012;26:106-116
    • (2012) Leukemia , vol.26 , pp. 106-116
    • Kim, C.H.1
  • 165
    • 84861820595 scopus 로고    scopus 로고
    • Antigen-presenting cell-derived complement modulates graft-versus-host disease
    • Kwan WH et al. Antigen-presenting cell-derived complement modulates graft-versus-host disease. J Clin Invest 2012;122:2234-2238
    • (2012) J Clin Invest , vol.122 , pp. 2234-2238
    • Kwan, W.H.1
  • 166
    • 80052259769 scopus 로고    scopus 로고
    • Renal thrombotic microangiopathy associated with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
    • Mii A et al. Renal thrombotic microangiopathy associated with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Pathol Int 2011;61:518-527
    • (2011) Pathol Int , vol.61 , pp. 518-527
    • Mii, A.1
  • 167
    • 84929046376 scopus 로고    scopus 로고
    • Hematopoietic stem cell transplantationassociated thrombotic microangiopathy accompanied by renal arteriolar C4d deposition
    • Sakamoto K et al. Hematopoietic stem cell transplantationassociated thrombotic microangiopathy accompanied by renal arteriolar C4d deposition. Pediatr Transplant 2015;19:E97-E100
    • (2015) Pediatr Transplant , vol.19 , pp. E97-E100
    • Sakamoto, K.1
  • 168
    • 84904861838 scopus 로고    scopus 로고
    • Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: A study in children and young adults
    • Jodele S et al. Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. Blood 2014;124:645-653
    • (2014) Blood , vol.124 , pp. 645-653
    • Jodele, S.1
  • 169
    • 27844507105 scopus 로고    scopus 로고
    • Hemolytic uremic syndrome after bone marrow transplantation: Clinical characteristics and outcome in children
    • Hale GA et al. Hemolytic uremic syndrome after bone marrow transplantation: clinical characteristics and outcome in children. Biol Blood Marrow Transplant 2005;11:912-920
    • (2005) Biol Blood Marrow Transplant , vol.11 , pp. 912-920
    • Hale, G.A.1
  • 170
    • 84885717017 scopus 로고    scopus 로고
    • Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy
    • Jodele S et al. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood 2013;122:2003-2007
    • (2013) Blood , vol.122 , pp. 2003-2007
    • Jodele, S.1
  • 171
    • 84960378679 scopus 로고    scopus 로고
    • The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy
    • Jodele S et al. The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy. Blood 2016;127:989-996
    • (2016) Blood , vol.127 , pp. 989-996
    • Jodele, S.1
  • 172
    • 84964855034 scopus 로고    scopus 로고
    • New approaches in the diagnosis, pathophysiology, and treatment of pediatric hematopoietic stem cell transplantation-associated thrombotic microangiopathy
    • Jodele S et al. New approaches in the diagnosis, pathophysiology, and treatment of pediatric hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Transfus Apher Sci 2016;54:181-190
    • (2016) Transfus Apher Sci , vol.54 , pp. 181-190
    • Jodele, S.1
  • 173
    • 84946895923 scopus 로고    scopus 로고
    • Use of eculizumab in patients with allogeneic stem cell transplant-associated thrombotic microangiopathy: A study from the SFGM-TC
    • de Fontbrune FS et al. Use of eculizumab in patients with allogeneic stem cell transplant-associated thrombotic microangiopathy: a study from the SFGM-TC. Transplantation 2015;99:1953-1959
    • (2015) Transplantation , vol.99 , pp. 1953-1959
    • De Fontbrune, F.S.1
  • 174
    • 84895786359 scopus 로고    scopus 로고
    • Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy
    • Jodele S et al. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Biol Blood Marrow Transplant 2014;20:518-525
    • (2014) Biol Blood Marrow Transplant , vol.20 , pp. 518-525
    • Jodele, S.1
  • 175
    • 84907206672 scopus 로고    scopus 로고
    • Hematopoietic transplant-associated thrombotic microangiopathy: Case report and review of diagnosis and treatments
    • Chapin J et al. Hematopoietic transplant-associated thrombotic microangiopathy: case report and review of diagnosis and treatments. Clin Adv Hematol Oncol 2014;12:565-573
    • (2014) Clin Adv Hematol Oncol , vol.12 , pp. 565-573
    • Chapin, J.1
  • 176
    • 84875803456 scopus 로고    scopus 로고
    • Successful use of eculizumab in a patient with post-transplant thrombotic microangiopathy
    • Peffault de Latour R et al. Successful use of eculizumab in a patient with post-transplant thrombotic microangiopathy. Br J Haematol 2013;161:279-280
    • (2013) Br J Haematol , vol.161 , pp. 279-280
    • Peffault De Latour, R.1
  • 177
    • 84905676449 scopus 로고    scopus 로고
    • Recovery from life-threatening transplantation-associated thrombotic microangiopathy using eculizumab in a patient with very severe aplastic anemia
    • Okano M et al. Recovery from life-threatening transplantation-associated thrombotic microangiopathy using eculizumab in a patient with very severe aplastic anemia. Bone Marrow Transplant 2014;49:1116-1118
    • (2014) Bone Marrow Transplant , vol.49 , pp. 1116-1118
    • Okano, M.1
  • 178
    • 85014540072 scopus 로고    scopus 로고
    • Renal and neurological response with eculizumab in a patient with transplant associated thrombotic microangiopathy after allogeneic hematopoietic progenitor cell transplantation
    • Sevindik OG et al. Renal and neurological response with eculizumab in a patient with transplant associated thrombotic microangiopathy after allogeneic hematopoietic progenitor cell transplantation. Case Rep Hematol 2015;2015:425410
    • (2015) Case Rep Hematol , vol.2015 , pp. 425410
    • Sevindik, O.G.1
  • 179
    • 85132482865 scopus 로고    scopus 로고
    • Eculizumab treatment in a patient with hematopoietic stem cell transplantation-associated thrombotic microangiopathy and steroid-refractory acute graft versus host disease
    • Fernandez C et al. Eculizumab treatment in a patient with hematopoietic stem cell transplantation-associated thrombotic microangiopathy and steroid-refractory acute graft versus host disease. Hematol Rep 2015;7:6107
    • (2015) Hematol Rep , vol.7 , pp. 6107
    • Fernandez, C.1
  • 180
    • 84963621743 scopus 로고    scopus 로고
    • Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy
    • Vasu S et al. Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy. Bone Marrow Transplant 2016;51:1241-1244
    • (2016) Bone Marrow Transplant , vol.51 , pp. 1241-1244
    • Vasu, S.1
  • 181
    • 22344434696 scopus 로고    scopus 로고
    • Blood and marrow transplant clinical trials network toxicity committee consensus summary: Thrombotic microangiopathy after hematopoietic stem cell transplantation
    • Ho VT et al. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005;11:571-575
    • (2005) Biol Blood Marrow Transplant , vol.11 , pp. 571-575
    • Ho, V.T.1
  • 182
    • 84951271153 scopus 로고    scopus 로고
    • Hematopoietic stem cell transplant-associated thrombotic microangiopathy
    • Elsallabi O et al. Hematopoietic stem cell transplant-associated thrombotic microangiopathy. Clin Appl Thromb Hemost 2016;22:12-20
    • (2016) Clin Appl Thromb Hemost , vol.22 , pp. 12-20
    • Elsallabi, O.1
  • 183
    • 34447626285 scopus 로고    scopus 로고
    • ABO-incompatible allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning: Close association with transplant-associated microangiopathy
    • Worel N et al. ABO-incompatible allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning: close association with transplant-associated microangiopathy. Transfus Apher Sci 2007;36:297-304
    • (2007) Transfus Apher Sci , vol.36 , pp. 297-304
    • Worel, N.1
  • 184
    • 34247895387 scopus 로고    scopus 로고
    • Successful treatment of thrombotic microangiopathy after haematopoietic stem cell transplantation with rituximab
    • Au WY et al. Successful treatment of thrombotic microangiopathy after haematopoietic stem cell transplantation with rituximab. Br J Haematol 2007;137:475-478
    • (2007) Br J Haematol , vol.137 , pp. 475-478
    • Au, W.Y.1
  • 185
    • 47849109877 scopus 로고    scopus 로고
    • Rituximab for allo-SCT-associated thrombotic thrombocytopenic purpura
    • Carella AM et al. Rituximab for allo-SCT-associated thrombotic thrombocytopenic purpura. Bone Marrow Transplant 2008;41:1063-1065
    • (2008) Bone Marrow Transplant , vol.41 , pp. 1063-1065
    • Carella, A.M.1
  • 186
    • 84901489226 scopus 로고    scopus 로고
    • Complement 5a receptor mediates angiotensin II-induced cardiac inflammation and remodeling
    • Zhang C et al. Complement 5a receptor mediates angiotensin II-induced cardiac inflammation and remodeling. Arterioscler Thromb Vasc Biol 2014;34:1240-1248
    • (2014) Arterioscler Thromb Vasc Biol , vol.34 , pp. 1240-1248
    • Zhang, C.1
  • 187
    • 84900873319 scopus 로고    scopus 로고
    • Antagonistof C5aR prevents cardiac remodeling in angiotensin II-induced hypertension
    • Zhang C et al. Antagonistof C5aR prevents cardiac remodeling in angiotensin II-induced hypertension. Am J Hypertens 2014;27:857-864
    • (2014) Am J Hypertens , vol.27 , pp. 857-864
    • Zhang, C.1
  • 188
    • 33947421167 scopus 로고    scopus 로고
    • Plasma levels of complement C3 is associated with development of hypertension: A longitudinal cohort study
    • Engstrom G et al. Plasma levels of complement C3 is associated with development of hypertension: a longitudinal cohort study. J Hum Hypertens 2007;21:276-282
    • (2007) J Hum Hypertens , vol.21 , pp. 276-282
    • Engstrom, G.1
  • 189
    • 84864348884 scopus 로고    scopus 로고
    • Associations of CFH polymorphisms and CFHR1-CFHR3 deletion with blood pressure and hypertension in Chinese population
    • Gan W et al. Associations of CFH polymorphisms and CFHR1-CFHR3 deletion with blood pressure and hypertension in Chinese population. PLoS One 2012;7:e42010
    • (2012) PLoS One , vol.7 , pp. e42010
    • Gan, W.1
  • 190
    • 79952934453 scopus 로고    scopus 로고
    • Clinical features of malignant hypertension with thrombotic microangiopathy
    • Akimoto T et al. Clinical features of malignant hypertension with thrombotic microangiopathy. Clin Exp Hypertens 2011;33:77-83
    • (2011) Clin Exp Hypertens , vol.33 , pp. 77-83
    • Akimoto, T.1
  • 191
    • 84993736115 scopus 로고    scopus 로고
    • Differentiating malignant hypertensioninduced thrombotic microangiopathy from thrombotic thrombocytopenic purpura
    • Khanal N et al. Differentiating malignant hypertensioninduced thrombotic microangiopathy from thrombotic thrombocytopenic purpura. Ther Adv Hematol 2015;6:97-102
    • (2015) Ther Adv Hematol , vol.6 , pp. 97-102
    • Khanal, N.1
  • 192
    • 84868350979 scopus 로고    scopus 로고
    • Malignant hypertension with reversible brainstem hypertensive encephalopathy and thrombotic microangiopathy
    • e17-e20
    • Deguchi I et al. Malignant hypertension with reversible brainstem hypertensive encephalopathy and thrombotic microangiopathy. J Stroke Cerebrovasc Dis 2012;21:915 e17-e20
    • (2012) J Stroke Cerebrovasc Dis , vol.21 , pp. 915
    • Deguchi, I.1
  • 193
    • 84880453521 scopus 로고    scopus 로고
    • Complement factor H mutations are present in ADAMTS13-deficient, ticlopidine-associated thrombotic microangiopathies
    • Chapin J et al. Complement factor H mutations are present in ADAMTS13-deficient, ticlopidine-associated thrombotic microangiopathies. Blood 2013;121:4012-4013
    • (2013) Blood , vol.121 , pp. 4012-4013
    • Chapin, J.1
  • 194
    • 84963516592 scopus 로고    scopus 로고
    • Clopidogrel-induced thrombotic microangiopathy in a patient with hypocomplementemia
    • Tada K et al. Clopidogrel-induced thrombotic microangiopathy in a patient with hypocomplementemia. Intern Med 2016;55:969-973
    • (2016) Intern Med , vol.55 , pp. 969-973
    • Tada, K.1
  • 195
    • 84885045257 scopus 로고    scopus 로고
    • Eculizumab and drug-induced haemolyticuraemic syndrome
    • Faguer S et al. Eculizumab and drug-induced haemolyticuraemic syndrome. Clin Kidney J 2013;6:484-485
    • (2013) Clin Kidney J , vol.6 , pp. 484-485
    • Faguer, S.1
  • 196
    • 85020614909 scopus 로고    scopus 로고
    • Use of eculizumab in refractory gemcitabine-induced thrombotic microangiopathy
    • Starck M, Wendtner CM. Use of eculizumab in refractory gemcitabine-induced thrombotic microangiopathy. Br J Haematol 2013
    • (2013) Br J Haematol
    • Starck, M.1    Wendtner, C.M.2
  • 197
    • 84989217805 scopus 로고    scopus 로고
    • Eculizumab therapy for gemcitabine induced hemolytic uremic syndrome: Case series and concise review
    • Al Ustwani O et al. Eculizumab therapy for gemcitabine induced hemolytic uremic syndrome: case series and concise review. J Gastrointest Oncol 2014;5:E30-E33
    • (2014) J Gastrointest Oncol , vol.5 , pp. E30-E33
    • Al Ustwani, O.1
  • 198
    • 85019827216 scopus 로고    scopus 로고
    • Gemcitabine-associated thrombotic microangiopathy: Response to complement inhibition and reinitiation of gemcitabine
    • Turner JL et al. Gemcitabine-associated thrombotic microangiopathy: response to complement inhibition and reinitiation of gemcitabine. Clin Colorectal Cancer 2016
    • (2016) Clin Colorectal Cancer
    • Turner, J.L.1
  • 199
    • 84983060381 scopus 로고    scopus 로고
    • Proteasome inhibitor associated thrombotic microangiopathy
    • Yui JC et al. Proteasome inhibitor associated thrombotic microangiopathy. AmJ Hematol 2016;91:E348-E352
    • (2016) AmJ Hematol , vol.91 , pp. E348-E352
    • Yui, J.C.1
  • 200
    • 0034674030 scopus 로고    scopus 로고
    • Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura
    • Tsai HM et al. Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura. Ann Intern Med 2000;132:794-799
    • (2000) Ann Intern Med , vol.132 , pp. 794-799
    • Tsai, H.M.1
  • 201
    • 70449560501 scopus 로고    scopus 로고
    • Is therapeutic plasma exchange indicated for patients with gemcitabine-induced hemolytic uremic syndrome?
    • Gore EM, Jones BS, Marques MB. Is therapeutic plasma exchange indicated for patients with gemcitabine-induced hemolytic uremic syndrome? J Clin Apher 2009;24:209-214
    • (2009) J Clin Apher , vol.24 , pp. 209-214
    • Gore, E.M.1    Jones, B.S.2    Marques, M.B.3
  • 202
    • 84962530615 scopus 로고    scopus 로고
    • Carfilzomib: A cause of drug associated thrombotic microangiopathy
    • Qaqish I et al. Carfilzomib: A cause of drug associated thrombotic microangiopathy. Transfus Apher Sci 2016;54:401-404
    • (2016) Transfus Apher Sci , vol.54 , pp. 401-404
    • Qaqish, I.1
  • 203
    • 33846445710 scopus 로고    scopus 로고
    • Disseminated malignancy misdiagnosed as thrombotic thrombocytopenic purpura: A report of 10 patients and a systematic review of published cases
    • Francis KK et al. Disseminated malignancy misdiagnosed as thrombotic thrombocytopenic purpura: A report of 10 patients and a systematic review of published cases. Oncologist 2007;12:11-19
    • (2007) Oncologist , vol.12 , pp. 11-19
    • Francis, K.K.1
  • 204
    • 0024391413 scopus 로고
    • Cancer-associated hemolytic-uremic syndrome: Analysis of 85 cases from a national registry
    • Lesesne JB et al. Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry. J Clin Oncol 1989;7:781-789
    • (1989) J Clin Oncol , vol.7 , pp. 781-789
    • Lesesne, J.B.1
  • 205
    • 70249131553 scopus 로고    scopus 로고
    • Cancer awareness in atypical thrombotic microangiopathies
    • Oberic L et al. Cancer awareness in atypical thrombotic microangiopathies. Oncologist 2009;14:769-779
    • (2009) Oncologist , vol.14 , pp. 769-779
    • Oberic, L.1
  • 206
    • 0029764359 scopus 로고    scopus 로고
    • Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5
    • Wang Y et al. Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc Natl Acad Sci USA 1996;93:8563-8568
    • (1996) Proc Natl Acad Sci USA , vol.93 , pp. 8563-8568
    • Wang, Y.1
  • 207
    • 84881389562 scopus 로고    scopus 로고
    • Targeting the complement system in systemic lupus erythematosus and other diseases
    • Barilla-Labarca ML, Toder K, Furie R. Targeting the complement system in systemic lupus erythematosus and other diseases. Clin Immunol 2013;148:313-321
    • (2013) Clin Immunol , vol.148 , pp. 313-321
    • Barilla-Labarca, M.L.1    Toder, K.2    Furie, R.3
  • 208
    • 79957991917 scopus 로고    scopus 로고
    • Association of genetic variants in complement factor H and factor H-related genes with systemic lupus erythematosus susceptibility
    • Zhao J et al. Association of genetic variants in complement factor H and factor H-related genes with systemic lupus erythematosus susceptibility. PLoS Genet 2011;7:e1002079
    • (2011) PLoS Genet , vol.7 , pp. e1002079
    • Zhao, J.1
  • 209
    • 84986207697 scopus 로고    scopus 로고
    • Use of eculizumab in atypical hemolytic uremic syndrome, complicating systemic lupus erythematosus
    • Bermea RS et al. Use of eculizumab in atypical hemolytic uremic syndrome, complicating systemic lupus erythematosus. J Clin Rheumatol 2016;22:320-323
    • (2016) J Clin Rheumatol , vol.22 , pp. 320-323
    • Bermea, R.S.1
  • 210
    • 84920942686 scopus 로고    scopus 로고
    • Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy
    • Coppo R et al. Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy. Pediatr Nephrol 2015;30:167-172
    • (2015) Pediatr Nephrol , vol.30 , pp. 167-172
    • Coppo, R.1
  • 211
    • 84922373286 scopus 로고    scopus 로고
    • Thrombotic microangiopathy in systemic lupus erythematosus: Efficacy of eculizumab
    • El-Husseini A et al. Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab. Am J Kidney Dis 2015;65:127-130
    • (2015) Am J Kidney Dis , vol.65 , pp. 127-130
    • El-Husseini, A.1
  • 212
    • 84983094382 scopus 로고    scopus 로고
    • Eculizumab as rescue therapy in severe resistant lupus nephritis
    • Pickering MC et al. Eculizumab as rescue therapy in severe resistant lupus nephritis. Rheumatology (Oxford) 2015;54:2286-2288
    • (2015) Rheumatology (Oxford) , vol.54 , pp. 2286-2288
    • Pickering, M.C.1
  • 213
    • 85068549807 scopus 로고    scopus 로고
    • Atypical hemolytic uremic syndrome secondary to lupus nephritis, responsive to eculizumab
    • Raufi AG et al. Atypical hemolytic uremic syndrome secondary to lupus nephritis, responsive to eculizumab. Hematol Rep 2016;8:6625
    • (2016) Hematol Rep , vol.8 , pp. 6625
    • Raufi, A.G.1
  • 214
    • 0345328706 scopus 로고    scopus 로고
    • Systemic lupus erythematosus and thrombotic thrombocytopenic purpura: A case report and literature review
    • Hamasaki K et al. Systemic lupus erythematosus and thrombotic thrombocytopenic purpura: a case report and literature review. Clin Rheumatol 2003;22:355-358
    • (2003) Clin Rheumatol , vol.22 , pp. 355-358
    • Hamasaki, K.1
  • 215
    • 70349569565 scopus 로고    scopus 로고
    • Role of tissue factor in a mouse model of thrombotic microangiopathy induced by antiphospholipid antibodies
    • Seshan SV et al. Role of tissue factor in a mouse model of thrombotic microangiopathy induced by antiphospholipid antibodies. Blood 2009;114:1675-1683
    • (2009) Blood , vol.114 , pp. 1675-1683
    • Seshan, S.V.1
  • 216
    • 0346969977 scopus 로고    scopus 로고
    • Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome
    • Girardi G et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 2003;112:1644-1654
    • (2003) J Clin Invest , vol.112 , pp. 1644-1654
    • Girardi, G.1
  • 217
    • 5444270100 scopus 로고    scopus 로고
    • A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice
    • Thurman JM et al. A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice. Mol Immunol 2005;42:87-97
    • (2005) Mol Immunol , vol.42 , pp. 87-97
    • Thurman, J.M.1
  • 218
    • 84908664176 scopus 로고    scopus 로고
    • Complement C5-inhibitor rEV576 (coversin) ameliorates in-vivo effects of antiphospholipid antibodies
    • Romay-Penabad Z et al. Complement C5-inhibitor rEV576 (coversin) ameliorates in-vivo effects of antiphospholipid antibodies. Lupus 2014;23:1324-1326
    • (2014) Lupus , vol.23 , pp. 1324-1326
    • Romay-Penabad, Z.1
  • 219
    • 84881372189 scopus 로고    scopus 로고
    • Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes
    • Canaud G et al. Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes. Am J Transplant 2013;13:2179-2185
    • (2013) Am J Transplant , vol.13 , pp. 2179-2185
    • Canaud, G.1
  • 220
    • 67449159236 scopus 로고    scopus 로고
    • Complement activation in patients with primary antiphospholipid syndrome
    • Oku K et al. Complement activation in patients with primary antiphospholipid syndrome. Ann Rheum Dis 2009;68:1030-1035
    • (2009) Ann Rheum Dis , vol.68 , pp. 1030-1035
    • Oku, K.1
  • 221
    • 77954767182 scopus 로고    scopus 로고
    • Renal involvement in primary antiphospholipid syndrome: Retrospective analysis of 160 patients
    • Sinico RA et al. Renal involvement in primary antiphospholipid syndrome: retrospective analysis of 160 patients. Clin J Am Soc Nephrol 2010;5:1211-1217
    • (2010) Clin J Am Soc Nephrol , vol.5 , pp. 1211-1217
    • Sinico, R.A.1
  • 222
    • 84943302788 scopus 로고    scopus 로고
    • Factor H autoantibodies in patients with antiphospholipid syndrome and thrombosis
    • Foltyn Zadura A et al. Factor H autoantibodies in patients with antiphospholipid syndrome and thrombosis. J Rheumatol 2015;42:1786-1793
    • (2015) J Rheumatol , vol.42 , pp. 1786-1793
    • Foltyn Zadura, A.1
  • 223
    • 85016048774 scopus 로고    scopus 로고
    • Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome
    • Barratt-Due A et al. Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome. Rheumatology (Oxford) 2016;55:1337-1339
    • (2016) Rheumatology (Oxford) , vol.55 , pp. 1337-1339
    • Barratt-Due, A.1
  • 224
    • 84917728306 scopus 로고    scopus 로고
    • Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: A case report
    • Kronbichler A et al. Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report. Medicine (Baltimore) 2014;93:e143
    • (2014) Medicine (Baltimore) , vol.93 , pp. e143
    • Kronbichler, A.1
  • 225
    • 84864485595 scopus 로고    scopus 로고
    • Brief report: Induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab
    • Shapira I et al. Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab. Arthritis Rheum 2012;64:2719-2723
    • (2012) Arthritis Rheum , vol.64 , pp. 2719-2723
    • Shapira, I.1
  • 226
    • 84961960857 scopus 로고    scopus 로고
    • A case of relapsing and refractory catastrophic anti-phospholipid syndrome successfully managed with eculizumab, a complement 5 inhibitor
    • Wig S et al. A case of relapsing and refractory catastrophic anti-phospholipid syndrome successfully managed with eculizumab, a complement 5 inhibitor. Rheumatology (Oxford) 2016;55:382-384
    • (2016) Rheumatology (Oxford) , vol.55 , pp. 382-384
    • Wig, S.1
  • 227
    • 84936987706 scopus 로고    scopus 로고
    • 36-year-old female with catastrophic antiphospholipid syndrome treated with eculizumab: A case report and review of literature
    • Strakhan M et al. 36-year-old female with catastrophic antiphospholipid syndrome treated with eculizumab: a case report and review of literature. Case Rep Hematol 2014;2014:704371
    • (2014) Case Rep Hematol , vol.2014 , pp. 704371
    • Strakhan, M.1
  • 228
    • 84940905884 scopus 로고    scopus 로고
    • Eculizumab induces sustained remission in a patient with refractory primary catastrophic antiphospholipid syndrome
    • Zikos TA et al. Eculizumab induces sustained remission in a patient with refractory primary catastrophic antiphospholipid syndrome. J Clin Rheumatol 2015;21:311-313
    • (2015) J Clin Rheumatol , vol.21 , pp. 311-313
    • Zikos, T.A.1
  • 229
    • 84857190406 scopus 로고    scopus 로고
    • Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation
    • Hadaya K et al. Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation. Am J Transplant 2011;11:2523-2527
    • (2011) Am J Transplant , vol.11 , pp. 2523-2527
    • Hadaya, K.1
  • 230
    • 84905733420 scopus 로고    scopus 로고
    • A case of thrombotic microangiopathy associated with antiphospholipid antibody syndrome successfully treated with eculizumab
    • Bakhtar O et al. A case of thrombotic microangiopathy associated with antiphospholipid antibody syndrome successfully treated with eculizumab. Transplantation 2014;98:e17-e18
    • (2014) Transplantation , vol.98 , pp. e17-e18
    • Bakhtar, O.1
  • 231
    • 84895064562 scopus 로고    scopus 로고
    • Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation
    • Lonze BE etal. Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation. Am J Transplant 2014;14:459-465
    • (2014) Am J Transplant , vol.14 , pp. 459-465
    • Lonze, B.E.1
  • 232
    • 84995665659 scopus 로고    scopus 로고
    • Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of 500 patients from the International CAPS Registry
    • Rodriguez-Pinto I et al. Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of 500 patients from the International CAPS Registry. Autoimmun Rev 2016
    • (2016) Autoimmun Rev
    • Rodriguez-Pinto, I.1
  • 233
    • 84904581191 scopus 로고    scopus 로고
    • Inhibition of the mTORC pathway in the antiphospholipid syndrome
    • Canaud G et al. Inhibition of the mTORC pathway in the antiphospholipid syndrome. N Engl J Med 2014;371:303-312
    • (2014) N Engl J Med , vol.371 , pp. 303-312
    • Canaud, G.1
  • 234
    • 62549104828 scopus 로고    scopus 로고
    • Is complement factor H a susceptibility factor for IgA nephropathy?
    • Edey M et al. Is complement factor H a susceptibility factor for IgA nephropathy? Mol Immunol 2009;46:1405-1408
    • (2009) Mol Immunol , vol.46 , pp. 1405-1408
    • Edey, M.1
  • 235
    • 0031822961 scopus 로고    scopus 로고
    • Glomerular deposition of mannose-binding lectin (MBL) indicates a novel mechanism of complement activation in IgA nephropathy
    • Endo M et al. Glomerular deposition of mannose-binding lectin (MBL) indicates a novel mechanism of complement activation in IgA nephropathy. Nephrol Dial Transplant 1998;13:1984-1990
    • (1998) Nephrol Dial Transplant , vol.13 , pp. 1984-1990
    • Endo, M.1
  • 236
    • 0031730769 scopus 로고    scopus 로고
    • Deposition of mannan binding protein and mannan binding protein-mediated complement activation in the glomeruli of patients with IgA nephropathy
    • Matsuda M et al. Deposition of mannan binding protein and mannan binding protein-mediated complement activation in the glomeruli of patients with IgA nephropathy. Nephron 1998;80:408-413
    • (1998) Nephron , vol.80 , pp. 408-413
    • Matsuda, M.1
  • 237
    • 0034751064 scopus 로고    scopus 로고
    • Mesangial IgA2 deposits and lectin pathwaymediated complement activation in IgA glomerulonephritis
    • Hisano S et al. Mesangial IgA2 deposits and lectin pathwaymediated complement activation in IgA glomerulonephritis. Am J Kidney Dis 2001;38:1082-1088
    • (2001) Am J Kidney Dis , vol.38 , pp. 1082-1088
    • Hisano, S.1
  • 238
    • 33646924264 scopus 로고    scopus 로고
    • Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease
    • Roos A et al. Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol 2006;17:1724-1734
    • (2006) J Am Soc Nephrol , vol.17 , pp. 1724-1734
    • Roos, A.1
  • 239
    • 0020120597 scopus 로고
    • Partial H (beta 1H) deficiency and glomerulonephritis in two families
    • Wyatt RJ et al. Partial H (beta 1H) deficiency and glomerulonephritis in two families. J Clin Immunol 1982;2:110-117
    • (1982) J Clin Immunol , vol.2 , pp. 110-117
    • Wyatt, R.J.1
  • 240
    • 79953224410 scopus 로고    scopus 로고
    • Genome-wide association study identifies susceptibility loci for IgA nephropathy
    • Gharavi AG et al. Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet 2011;43:321-327
    • (2011) Nat Genet , vol.43 , pp. 321-327
    • Gharavi, A.G.1
  • 241
    • 84999762007 scopus 로고    scopus 로고
    • Rare variants in the complement factor hrelated protein 5 gene contribute to genetic susceptibility to IgA nephropathy
    • Zhai YL et al. Rare variants in the complement factor hrelated protein 5 gene contribute to genetic susceptibility to IgA nephropathy. J Am Soc Nephrol 2016;27:2894-2905
    • (2016) J Am Soc Nephrol , vol.27 , pp. 2894-2905
    • Zhai, Y.L.1
  • 242
    • 84954067521 scopus 로고    scopus 로고
    • Use of eculizumab in crescentic IgA nephropathy: Proof of principle and conundrum?
    • Ring T et al. Use of eculizumab in crescentic IgA nephropathy: proof of principle and conundrum? Clin Kidney J 2015;8:489-491
    • (2015) Clin Kidney J , vol.8 , pp. 489-491
    • Ring, T.1
  • 243
    • 84930703194 scopus 로고    scopus 로고
    • Eculizumab treatment for rescue of renal function in IgA nephropathy
    • Rosenblad T et al. Eculizumab treatment for rescue of renal function in IgA nephropathy. Pediatr Nephrol 2014;29:2225-2228
    • (2014) Pediatr Nephrol , vol.29 , pp. 2225-2228
    • Rosenblad, T.1
  • 244
    • 59949101550 scopus 로고    scopus 로고
    • C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis
    • Schreiber A et al. C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J Am Soc Nephrol 2009;20:289-298
    • (2009) J Am Soc Nephrol , vol.20 , pp. 289-298
    • Schreiber, A.1
  • 245
    • 33847052568 scopus 로고    scopus 로고
    • Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies
    • Xiao H et al. Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol 2007;170:52-64
    • (2007) Am J Pathol , vol.170 , pp. 52-64
    • Xiao, H.1
  • 246
    • 84893502246 scopus 로고    scopus 로고
    • C5a receptor (CD88) blockade protects against MPO-ANCA GN
    • Xiao H et al. C5a receptor (CD88) blockade protects against MPO-ANCA GN. J Am Soc Nephrol 2014;25:225-231
    • (2014) J Am Soc Nephrol , vol.25 , pp. 225-231
    • Xiao, H.1
  • 247
    • 84991696423 scopus 로고    scopus 로고
    • Antineutrophilic cytoplasmic antibodyassociated vasculitis with hypocomplementemia has a higher incidence of serious organ damage and a poor prognosis
    • Fukui S et al. Antineutrophilic cytoplasmic antibodyassociated vasculitis with hypocomplementemia has a higher incidence of serious organ damage and a poor prognosis. Medicine (Baltimore) 2016;95:e4871
    • (2016) Medicine (Baltimore) , vol.95 , pp. e4871
    • Fukui, S.1
  • 248
    • 84957800791 scopus 로고    scopus 로고
    • Association of serum C3 concentration and histologic signs of thrombotic microangiopathy with outcomes among patients with ANCA-associated renal vasculitis
    • Manenti L et al. Association of serum C3 concentration and histologic signs of thrombotic microangiopathy with outcomes among patients with ANCA-associated renal vasculitis. Clin J Am Soc Nephrol 2015;10:2143-2151
    • (2015) Clin J Am Soc Nephrol , vol.10 , pp. 2143-2151
    • Manenti, L.1
  • 249
    • 84978758911 scopus 로고    scopus 로고
    • Complement in ANCA-associated glomerulonephritis
    • Hilhorst M et al. Complement in ANCA-associated glomerulonephritis. Nephrol Dial Transplant 2015
    • (2015) Nephrol Dial Transplant
    • Hilhorst, M.1
  • 250
    • 77954632414 scopus 로고    scopus 로고
    • Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis
    • Jones RB et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010;363:211-220
    • (2010) N Engl J Med , vol.363 , pp. 211-220
    • Jones, R.B.1
  • 251
    • 84926432207 scopus 로고    scopus 로고
    • Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement
    • Geetha D et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement. J Am Soc Nephrol 2015;26:976-985
    • (2015) J Am Soc Nephrol , vol.26 , pp. 976-985
    • Geetha, D.1
  • 252
    • 84886298109 scopus 로고    scopus 로고
    • The role of complement in membranous nephropathy
    • Ma H, Sandor DG, Beck LH Jr. The role of complement in membranous nephropathy. Semin Nephrol 2013;33:531-542
    • (2013) Semin Nephrol , vol.33 , pp. 531-542
    • Ma, H.1    Sandor, D.G.2    Beck, L.H.3
  • 253
    • 4444239340 scopus 로고    scopus 로고
    • Glomerular deposition and urinary excretion of complement factor H in idiopathic membranous nephropathy
    • Endo M et al. Glomerular deposition and urinary excretion of complement factor H in idiopathic membranous nephropathy. Nephron Clin Pract 2004;97:c147-c153
    • (2004) Nephron Clin Pract , vol.97 , pp. c147-c153
    • Endo, M.1
  • 254
    • 77951253923 scopus 로고    scopus 로고
    • IgG subclasses and complement pathway in segmental and global membranous nephropathy
    • Segawa Y et al. IgG subclasses and complement pathway in segmental and global membranous nephropathy. Pediatr Nephrol 2010;25:1091-1099
    • (2010) Pediatr Nephrol , vol.25 , pp. 1091-1099
    • Segawa, Y.1
  • 255
    • 23944438985 scopus 로고    scopus 로고
    • Cellular response to injury in membranous nephropathy
    • Nangaku M, Shankland SJ, Couser WG. Cellular response to injury in membranous nephropathy. J Am Soc Nephrol 2005;16:1195-1204
    • (2005) J Am Soc Nephrol , vol.16 , pp. 1195-1204
    • Nangaku, M.1    Shankland, S.J.2    Couser, W.G.3
  • 256
    • 34249894713 scopus 로고    scopus 로고
    • A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy
    • Jha V et al. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol 2007;18:1899-1904
    • (2007) J Am Soc Nephrol , vol.18 , pp. 1899-1904
    • Jha, V.1
  • 257
    • 0023775708 scopus 로고
    • Micro-angiopathic haemolysis, thrombocytopenia and nephrotic syndrome associated with membranous nephropathy in a Vietnamese boy
    • McDonald DT, Roy LP. Micro-angiopathic haemolysis, thrombocytopenia and nephrotic syndrome associated with membranous nephropathy in a Vietnamese boy. Aust Paediatr J 1988;24:311-313
    • (1988) Aust Paediatr J , vol.24 , pp. 311-313
    • McDonald, D.T.1    Roy, L.P.2
  • 258
    • 84884513282 scopus 로고    scopus 로고
    • Atypical haemolytic uraemic syndrome with underlying glomerulopathies. A case series and a review of the literature
    • Manenti L et al. Atypical haemolytic uraemic syndrome with underlying glomerulopathies. A case series and a review of the literature. Nephrol Dial Transplant 2013;28:2246-2259
    • (2013) Nephrol Dial Transplant , vol.28 , pp. 2246-2259
    • Manenti, L.1
  • 259
    • 11144342822 scopus 로고    scopus 로고
    • Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): Report of three cases
    • Koulova L et al. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases. Am J Hematol 2005;78:49-54
    • (2005) Am J Hematol , vol.78 , pp. 49-54
    • Koulova, L.1
  • 260
    • 70249084198 scopus 로고    scopus 로고
    • Membranous nephropathy and thrombotic thrombocytopenic purpura treated with rituximab
    • Kuppachi S, Chander P, Yoo J. Membranous nephropathy and thrombotic thrombocytopenic purpura treated with rituximab. J Nephrol 2009;22:561-564
    • (2009) J Nephrol , vol.22 , pp. 561-564
    • Kuppachi, S.1    Chander, P.2    Yoo, J.3
  • 261
    • 84947460124 scopus 로고    scopus 로고
    • Complement activation in patients with focal segmental glomerulosclerosis
    • Thurman JM et al. Complement activation in patients with focal segmental glomerulosclerosis. PLoS One 2015;10:e0136558
    • (2015) PLoS One , vol.10 , pp. e0136558
    • Thurman, J.M.1
  • 262
    • 85021137566 scopus 로고    scopus 로고
    • Clinical significance of IgM and C3 glomerular deposition in primary focal segmental glomerulosclerosis
    • Zhang YM et al. Clinical significance of IgM and C3 glomerular deposition in primary focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2016;11:1582-1589
    • (2016) Clin J Am Soc Nephrol , vol.11 , pp. 1582-1589
    • Zhang, Y.M.1
  • 263
    • 85038031095 scopus 로고    scopus 로고
    • Thrombotic microangiopathy in inverted formin 2-mediated renal disease
    • Challis RC et al. Thrombotic microangiopathy in inverted formin 2-mediated renal disease. J Am Soc Nephrol 2016
    • (2016) J Am Soc Nephrol
    • Challis, R.C.1
  • 264
    • 59149100961 scopus 로고    scopus 로고
    • Renal biopsy findings predicting outcome in scleroderma renal crisis
    • Batal I et al. Renal biopsy findings predicting outcome in scleroderma renal crisis. Hum Pathol 2009;40:332-340
    • (2009) Hum Pathol , vol.40 , pp. 332-340
    • Batal, I.1
  • 265
    • 84922695299 scopus 로고    scopus 로고
    • The local complement activation on vascular bed of patients with systemic sclerosis: A hypothesisgenerating study
    • Scambi C et al. The local complement activation on vascular bed of patients with systemic sclerosis: a hypothesisgenerating study. PLoS One 2015;10:e0114856
    • (2015) PLoS One , vol.10 , pp. e0114856
    • Scambi, C.1
  • 266
    • 84982804500 scopus 로고    scopus 로고
    • Complement activation and effect of eculizumab in scleroderma renal crisis
    • Devresse A et al. Complement activation and effect of eculizumab in scleroderma renal crisis. Medicine (Baltimore) 2016;95:e4459
    • (2016) Medicine (Baltimore) , vol.95 , pp. e4459
    • Devresse, A.1
  • 267
    • 84959365593 scopus 로고    scopus 로고
    • Eculizumab for rescue of thrombotic microangiopathy in PM-Scl antibody-positive autoimmune overlap syndrome
    • Thomas CP et al. Eculizumab for rescue of thrombotic microangiopathy in PM-Scl antibody-positive autoimmune overlap syndrome. Clin Kidney J 2015;8:698-701
    • (2015) Clin Kidney J , vol.8 , pp. 698-701
    • Thomas, C.P.1
  • 268
    • 84988372364 scopus 로고    scopus 로고
    • Scleroderma renal crisis and renal involvement in systemic sclerosis
    • Woodworth TG et al. Scleroderma renal crisis and renal involvement in systemic sclerosis. Nat Rev Nephrol 2016
    • (2016) Nat Rev Nephrol
    • Woodworth, T.G.1
  • 269
    • 84871212143 scopus 로고    scopus 로고
    • Prognosis of scleroderma renal crisis: A longterm observational study
    • Cozzi F et al. Prognosis of scleroderma renal crisis: a longterm observational study. Nephrol Dial Transplant 2012;27:4398-4403
    • (2012) Nephrol Dial Transplant , vol.27 , pp. 4398-4403
    • Cozzi, F.1
  • 270
    • 33745441327 scopus 로고    scopus 로고
    • Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice
    • Pickering MC et al. Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice. Proc Natl Acad Sci USA 2006;103:9649-9654
    • (2006) Proc Natl Acad Sci USA , vol.103 , pp. 9649-9654
    • Pickering, M.C.1
  • 271
    • 84864554927 scopus 로고    scopus 로고
    • Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies
    • Servais A et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 2012;82:454-464
    • (2012) Kidney Int , vol.82 , pp. 454-464
    • Servais, A.1
  • 272
    • 84958237174 scopus 로고    scopus 로고
    • Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome
    • Iatropoulos P et al. Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. Mol Immunol 2016;71:131-142
    • (2016) Mol Immunol , vol.71 , pp. 131-142
    • Iatropoulos, P.1
  • 273
    • 84860779074 scopus 로고    scopus 로고
    • Eculizumab for dense deposit disease and C3 glomerulonephritis
    • Bomback AS et al. Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol 2012;7:748-756
    • (2012) Clin J Am Soc Nephrol , vol.7 , pp. 748-756
    • Bomback, A.S.1
  • 274
    • 84858633062 scopus 로고    scopus 로고
    • Eculizumab and refractory membranoproliferative glomerulonephritis
    • Radhakrishnan S et al. Eculizumab and refractory membranoproliferative glomerulonephritis. N Engl J Med 2012;366:1165-1166
    • (2012) N Engl J Med , vol.366 , pp. 1165-1166
    • Radhakrishnan, S.1
  • 275
    • 84863881370 scopus 로고    scopus 로고
    • Thrombotic microangiopathy mimicking membranoproliferative glomerulonephritis
    • Brackman D et al. Thrombotic microangiopathy mimicking membranoproliferative glomerulonephritis. Nephrol Dial Transplant 2011;26:3399-3403
    • (2011) Nephrol Dial Transplant , vol.26 , pp. 3399-3403
    • Brackman, D.1
  • 276
    • 84883261341 scopus 로고    scopus 로고
    • Eculizumab and recurrent C3 glomerulonephritis
    • Gurkan S et al. Eculizumab and recurrent C3 glomerulonephritis. Pediatr Nephrol 2013;28:1975-1981
    • (2013) Pediatr Nephrol , vol.28 , pp. 1975-1981
    • Gurkan, S.1
  • 277
    • 84990841054 scopus 로고    scopus 로고
    • Severe active C3 glomerulonephritis triggered by immune complexes and inactivated after eculizumab therapy
    • Kersnik Levart T et al. Severe active C3 glomerulonephritis triggered by immune complexes and inactivated after eculizumab therapy. Diagn Pathol 2016;11:94
    • (2016) Diagn Pathol , vol.11 , pp. 94
    • Kersnik Levart, T.1
  • 278
    • 84959490254 scopus 로고    scopus 로고
    • Discontinuation of dialysis with eculizumab therapy in a pediatric patient with dense deposit disease
    • Tran CL et al. Discontinuation of dialysis with eculizumab therapy in a pediatric patient with dense deposit disease. Pediatr Nephrol 2016;31:683-687
    • (2016) Pediatr Nephrol , vol.31 , pp. 683-687
    • Tran, C.L.1
  • 279
    • 84858661698 scopus 로고    scopus 로고
    • Eculizumab for the treatment of dense-deposit disease
    • Vivarelli M, Pasini A, Emma F. Eculizumab for the treatment of dense-deposit disease. N Engl J Med 2012;366:1163-1165
    • (2012) N Engl J Med , vol.366 , pp. 1163-1165
    • Vivarelli, M.1    Pasini, A.2    Emma, F.3
  • 280
    • 84901641827 scopus 로고    scopus 로고
    • Rituximab fails where eculizumab restores renal function in C3nef-related DDD
    • Rousset-Rouviere C et al. Rituximab fails where eculizumab restores renal function in C3nef-related DDD. Pediatr Nephrol 2014;29:1107-1111
    • (2014) Pediatr Nephrol , vol.29 , pp. 1107-1111
    • Rousset-Rouviere, C.1
  • 281
    • 84939939865 scopus 로고    scopus 로고
    • A case of C3 glomerulonephritis successfully treated with eculizumab
    • Payette A et al. A case of C3 glomerulonephritis successfully treated with eculizumab. Pediatr Nephrol 2015;30:1033-1037
    • (2015) Pediatr Nephrol , vol.30 , pp. 1033-1037
    • Payette, A.1
  • 282
    • 84858671433 scopus 로고    scopus 로고
    • Eculizumab in a patient with dense-deposit disease
    • Daina E, Noris M, Remuzzi G. Eculizumab in a patient with dense-deposit disease. N Engl J Med 2012;366:1161-1163
    • (2012) N Engl J Med , vol.366 , pp. 1161-1163
    • Daina, E.1    Noris, M.2    Remuzzi, G.3
  • 283
    • 84942087191 scopus 로고    scopus 로고
    • Eculizumab-induced reversal of dialysisdependent kidney failure from C3 glomerulonephritis
    • Inman M et al. Eculizumab-induced reversal of dialysisdependent kidney failure from C3 glomerulonephritis. Clin Kidney J 2015;8:445-448
    • (2015) Clin Kidney J , vol.8 , pp. 445-448
    • Inman, M.1
  • 284
    • 84924119716 scopus 로고    scopus 로고
    • Eculizumab for treatment of rapidly progressive C3 glomerulopathy
    • Le Quintrec M et al. Eculizumab for treatment of rapidly progressive C3 glomerulopathy. Am J Kidney Dis 2015;65:484-489
    • (2015) Am J Kidney Dis , vol.65 , pp. 484-489
    • Le Quintrec, M.1
  • 285
    • 84943795891 scopus 로고    scopus 로고
    • Eculizumab in pediatric dense deposit disease
    • Oosterveld MJ et al. Eculizumab in pediatric dense deposit disease. Clin J Am Soc Nephrol 2015;10:1773-1782
    • (2015) Clin J Am Soc Nephrol , vol.10 , pp. 1773-1782
    • Oosterveld, M.J.1
  • 286
    • 84901672159 scopus 로고    scopus 로고
    • Eculizumab therapy in a patient with densedeposit disease associated with partial lipodystropy
    • Ozkaya O et al. Eculizumab therapy in a patient with densedeposit disease associated with partial lipodystropy. Pediatr Nephrol 2014;29:1283-1287
    • (2014) Pediatr Nephrol , vol.29 , pp. 1283-1287
    • Ozkaya, O.1
  • 287
    • 84859421387 scopus 로고    scopus 로고
    • Recurrent dense deposit disease after renal transplantation: An emerging role for complementary therapies
    • McCaughan JA, O'Rourke DM, Courtney AE. Recurrent dense deposit disease after renal transplantation: an emerging role for complementary therapies. Am J Transplant 2012;12:1046-1051
    • (2012) Am J Transplant , vol.12 , pp. 1046-1051
    • McCaughan, J.A.1    O'Rourke, D.M.2    Courtney, A.E.3
  • 288
    • 84930251736 scopus 로고    scopus 로고
    • Eculizumab in dense-deposit disease after renal transplantation
    • Sanchez-Moreno A et al. Eculizumab in dense-deposit disease after renal transplantation. Pediatr Nephrol 2014;29:2055-2059
    • (2014) Pediatr Nephrol , vol.29 , pp. 2055-2059
    • Sanchez-Moreno, A.1
  • 289
    • 84979198208 scopus 로고    scopus 로고
    • Complement, thrombotic microangiopathy and disseminated intravascular coagulation
    • Kurosawa S, Stearns-Kurosawa DJ. Complement, thrombotic microangiopathy and disseminated intravascular coagulation. J Intensive Care 2014;2:65
    • (2014) J Intensive Care , vol.2 , pp. 65
    • Kurosawa, S.1    Stearns-Kurosawa, D.J.2
  • 290
    • 84947260202 scopus 로고    scopus 로고
    • An international consensus approach to the management of atypical hemolytic uremic syndrome in children
    • Loirat C et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol 2016;31:15-39
    • (2016) Pediatr Nephrol , vol.31 , pp. 15-39
    • Loirat, C.1
  • 291
    • 84964533992 scopus 로고    scopus 로고
    • Eculizumab in children with hemolytic uremic syndrome
    • Kavanagh D, Smith-Jackson K. Eculizumab in children with hemolytic uremic syndrome. Kidney Int 2016;89:537-538
    • (2016) Kidney Int , vol.89 , pp. 537-538
    • Kavanagh, D.1    Smith-Jackson, K.2
  • 292
    • 84973267298 scopus 로고    scopus 로고
    • Patient stratification and therapy in atypical haemolytic uraemic syndrome (aHUS)
    • Wong E et al. Patient stratification and therapy in atypical haemolytic uraemic syndrome (aHUS). Immunobiology 2016;221:715-718
    • (2016) Immunobiology , vol.221 , pp. 715-718
    • Wong, E.1
  • 293
    • 77957602545 scopus 로고    scopus 로고
    • Transplantation in atypical hemolytic uremic syndrome
    • Kavanagh D et al. Transplantation in atypical hemolytic uremic syndrome. Semin Thromb Hemost 2010;36:653-659
    • (2010) Semin Thromb Hemost , vol.36 , pp. 653-659
    • Kavanagh, D.1
  • 294
    • 0142250921 scopus 로고    scopus 로고
    • Thrombotic microangiopathy after renal transplantation in the United States
    • Reynolds JC et al. Thrombotic microangiopathy after renal transplantation in the United States. Am J Kidney Dis 2003;42:1058-1068
    • (2003) Am J Kidney Dis , vol.42 , pp. 1058-1068
    • Reynolds, J.C.1
  • 295
    • 33748512369 scopus 로고    scopus 로고
    • Thrombotic microangiopathy after kidney transplantation
    • Ponticelli C, Banfi G. Thrombotic microangiopathy after kidney transplantation. Transpl Int 2006;19:789-794
    • (2006) Transpl Int , vol.19 , pp. 789-794
    • Ponticelli, C.1    Banfi, G.2
  • 296
    • 84884821706 scopus 로고    scopus 로고
    • Targeted strategies in the prevention and managementof atypical HUS recurrence after kidney transplantation
    • Zuber J et al. Targeted strategies in the prevention and managementof atypical HUS recurrence after kidney transplantation. Transplant Rev (Orlando) 2013;27:117-125
    • (2013) Transplant Rev (Orlando) , vol.27 , pp. 117-125
    • Zuber, J.1
  • 297
    • 84923996371 scopus 로고    scopus 로고
    • De novo thrombotic microangiopathy after non-renal solid organ transplantation
    • Verbiest A, Pirenne J, Dierickx D. De novo thrombotic microangiopathy after non-renal solid organ transplantation. Blood Rev 2014;28:269-279
    • (2014) Blood Rev , vol.28 , pp. 269-279
    • Verbiest, A.1    Pirenne, J.2    Dierickx, D.3
  • 298
    • 77954901670 scopus 로고    scopus 로고
    • De novo thrombotic microangiopathy in renal allograft biopsies-role of antibody-mediated rejection
    • Satoskar AA et al. De novo thrombotic microangiopathy in renal allograft biopsies-role of antibody-mediated rejection. Am J Transplant 2010;10:1804-1811
    • (2010) Am J Transplant , vol.10 , pp. 1804-1811
    • Satoskar, A.A.1
  • 299
    • 84959440372 scopus 로고    scopus 로고
    • The Revised (2013) Banff Classification for antibody-mediated rejection of renal allografts: Update, difficulties, and future considerations
    • Haas M. The Revised (2013) Banff Classification for antibody-mediated rejection of renal allografts: update, difficulties, and future considerations. Am J Transplant 2016;16:1352-1357
    • (2016) Am J Transplant , vol.16 , pp. 1352-1357
    • Haas, M.1
  • 300
    • 84874633763 scopus 로고    scopus 로고
    • DGKE variants cause a glomerular microangiopathy that mimics membranoproliferative GN
    • Ozaltin F et al. DGKE variants cause a glomerular microangiopathy that mimics membranoproliferative GN. J Am Soc Nephrol 2013;24:377-384
    • (2013) J Am Soc Nephrol , vol.24 , pp. 377-384
    • Ozaltin, F.1
  • 301
    • 84867997580 scopus 로고    scopus 로고
    • STEC-HUS, atypical HUS and TTP are all diseases of complement activation
    • Noris M, Mescia F, Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol 2012;8:622-633
    • (2012) Nat Rev Nephrol , vol.8 , pp. 622-633
    • Noris, M.1    Mescia, F.2    Remuzzi, G.3
  • 303
    • 84964765602 scopus 로고    scopus 로고
    • Pregnancy-related thrombotic microangiopathies: Clues from complement biology
    • Fakhouri F. Pregnancy-related thrombotic microangiopathies: Clues from complement biology. Transfus Apher Sci 2016;54:199-202
    • (2016) Transfus Apher Sci , vol.54 , pp. 199-202
    • Fakhouri, F.1
  • 304
    • 0042703238 scopus 로고    scopus 로고
    • The association of pregnancy with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome
    • George JN. The association of pregnancy with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol 2003;10:339-344
    • (2003) Curr Opin Hematol , vol.10 , pp. 339-344
    • George, J.N.1
  • 305
    • 84876823275 scopus 로고    scopus 로고
    • Obstetric nephrology: AKI and thrombotic microangiopathies in pregnancy
    • Fakhouri F, Vercel C, Fremeaux-Bacchi V. Obstetric nephrology: AKI and thrombotic microangiopathies in pregnancy. Clin J Am Soc Nephrol 2012;7:2100-2106
    • (2012) Clin J Am Soc Nephrol , vol.7 , pp. 2100-2106
    • Fakhouri, F.1    Vercel, C.2    Fremeaux-Bacchi, V.3
  • 306
    • 77956061313 scopus 로고    scopus 로고
    • Pre-eclampsia
    • Steegers EA et al. Pre-eclampsia. Lancet 2010;376:631-644
    • (2010) Lancet , vol.376 , pp. 631-644
    • Steegers, E.A.1
  • 307
    • 0036707878 scopus 로고    scopus 로고
    • Molecular basis for high renal cell sensitivity to the cytotoxic effects of shigatoxin-1: Upregulation of globotriaosylceramide expression
    • Hughes AK et al. Molecular basis for high renal cell sensitivity to the cytotoxic effects of shigatoxin-1: upregulation of globotriaosylceramide expression. J Am Soc Nephrol 2002;13:2239-2245
    • (2002) J Am Soc Nephrol , vol.13 , pp. 2239-2245
    • Hughes, A.K.1
  • 308
    • 79952087639 scopus 로고    scopus 로고
    • Escherichia coli Shiga toxin mechanisms of action in renal disease
    • Obrig TG. Escherichia coli Shiga toxin mechanisms of action in renal disease. Toxins (Basel) 2010;2:2769-2794
    • (2010) Toxins (Basel) , vol.2 , pp. 2769-2794
    • Obrig, T.G.1
  • 309
    • 68549099868 scopus 로고    scopus 로고
    • Pathogenesis of thrombotic microangiopathy: Insights from animal models
    • Richards A, Kavanagh D. Pathogenesis of thrombotic microangiopathy: insights from animal models. Nephron Exp Nephrol 2009;113:e97-e103
    • (2009) Nephron Exp Nephrol , vol.113 , pp. e97-e103
    • Richards, A.1    Kavanagh, D.2
  • 310
    • 84941369290 scopus 로고    scopus 로고
    • Eculizumab in typical hemolytic uremic syndrome (HUS) with neurological involvement
    • Pape L et al. Eculizumab in typical hemolytic uremic syndrome (HUS) with neurological involvement. Medicine (Baltimore) 2015;94:e1000
    • (2015) Medicine (Baltimore) , vol.94 , pp. e1000
    • Pape, L.1
  • 311
    • 84867993202 scopus 로고    scopus 로고
    • Renal and neurological involvement in typical Shiga toxin-associated HUS
    • Trachtman H et al. Renal and neurological involvement in typical Shiga toxin-associated HUS. Nat Rev Nephrol 2012;8:658-669
    • (2012) Nat Rev Nephrol , vol.8 , pp. 658-669
    • Trachtman, H.1
  • 312
    • 80051916351 scopus 로고    scopus 로고
    • Streptococcus pneumoniae-associated hemolytic uremic syndrome among children in North America
    • Banerjee R et al. Streptococcus pneumoniae-associated hemolytic uremic syndrome among children in North America. Pediatr Infect DisJ 2011;30:736-739
    • (2011) Pediatr Infect DisJ , vol.30 , pp. 736-739
    • Banerjee, R.1
  • 313
    • 84855182718 scopus 로고    scopus 로고
    • Invasive pneumococcal pneumonia is the major cause of paediatric haemolytic-uraemic syndrome in Taiwan
    • Lee CS et al. Invasive pneumococcal pneumonia is the major cause of paediatric haemolytic-uraemic syndrome in Taiwan. Nephrology (Carlton) 2012;17:48-52
    • (2012) Nephrology (Carlton) , vol.17 , pp. 48-52
    • Lee, C.S.1
  • 314
    • 73449116405 scopus 로고    scopus 로고
    • Ten years of pneumococcalassociated haemolytic uraemic syndrome in New Zealand children
    • Prestidge C, Wong W. Ten years of pneumococcalassociated haemolytic uraemic syndrome in New Zealand children. J Paediatr Child Health 2009;45:731-735
    • (2009) J Paediatr Child Health , vol.45 , pp. 731-735
    • Prestidge, C.1    Wong, W.2
  • 315
    • 34447539658 scopus 로고    scopus 로고
    • Hemolytic uremic syndrome associated with invasive pneumococcal disease: The United Kingdom experience
    • Waters AM et al. Hemolytic uremic syndrome associated with invasive pneumococcal disease: the United Kingdom experience. J Pediatr 2007;151:140-144
    • (2007) J Pediatr , vol.151 , pp. 140-144
    • Waters, A.M.1
  • 316
    • 84924894624 scopus 로고    scopus 로고
    • Structural basis for sialic acid-mediated self-recognition by complement factor H
    • Blaum BS et al. Structural basis for sialic acid-mediated self-recognition by complement factor H. Nat Chem Biol 2015;11:77-82
    • (2015) Nat Chem Biol , vol.11 , pp. 77-82
    • Blaum, B.S.1
  • 317
    • 79961011284 scopus 로고    scopus 로고
    • Viral-associated thrombotic microangiopathies
    • Lopes da Silva R. Viral-associated thrombotic microangiopathies. Hematol Oncol Stem Cell Ther 2011;4:51-59
    • (2011) Hematol Oncol Stem Cell Ther , vol.4 , pp. 51-59
    • Lopes Da Silva, R.1
  • 318
    • 0036151680 scopus 로고    scopus 로고
    • Cellular injury associated with renal thrombotic microangiopathy in human immunodeficiency virusinfected macaques
    • Segerer S et al. Cellular injury associated with renal thrombotic microangiopathy in human immunodeficiency virusinfected macaques. J Am Soc Nephrol 2002;13:370-378
    • (2002) J Am Soc Nephrol , vol.13 , pp. 370-378
    • Segerer, S.1
  • 319
    • 85038028809 scopus 로고    scopus 로고
    • Is complement blockade an acceptable therapeutic strategy for hematopoietic cell transplantassociated thrombotic microangiopathy?
    • Dhakal P, Bhatt VR. Is complement blockade an acceptable therapeutic strategy for hematopoietic cell transplantassociated thrombotic microangiopathy? Bone Marrow Transplant 2016
    • (2016) Bone Marrow Transplant
    • Dhakal, P.1    Bhatt, V.R.2
  • 320
    • 13144265709 scopus 로고    scopus 로고
    • Microangiopathic hemolysis and renal failure in malignant hypertension
    • van den Born BJ et al. Microangiopathic hemolysis and renal failure in malignant hypertension. Hypertension 2005;45:246-251
    • (2005) Hypertension , vol.45 , pp. 246-251
    • Van Den Born, B.J.1
  • 321
    • 34547418087 scopus 로고    scopus 로고
    • The renin-angiotensin system in malignant hypertension revisited: Plasma renin activity, microangiopathic hemolysis, and renal failure in malignant hypertension
    • van den Born BJ, Koopmans RP, van Montfrans GA. The renin-angiotensin system in malignant hypertension revisited: plasma renin activity, microangiopathic hemolysis, and renal failure in malignant hypertension. Am J Hypertens 2007;20:900-906
    • (2007) Am J Hypertens , vol.20 , pp. 900-906
    • Van Den Born, B.J.1    Koopmans, R.P.2    Van Montfrans, G.A.3
  • 322
    • 84864371299 scopus 로고    scopus 로고
    • Long-term renal outcome in patients with malignant hypertension: A retrospective cohort study
    • Amraoui F et al. Long-term renal outcome in patients with malignant hypertension: a retrospective cohort study. BMC Nephrol 2012;13:71
    • (2012) BMC Nephrol , vol.13 , pp. 71
    • Amraoui, F.1
  • 323
    • 85019135806 scopus 로고    scopus 로고
    • Severe hypertension with renal thrombotic microangiopathy: What happened to the usual suspect?
    • Van Laecke S, Van Biesen W. Severe hypertension with renal thrombotic microangiopathy: what happened to the usual suspect? Kidney Int 2017;91:1271-1274
    • (2017) Kidney Int , vol.91 , pp. 1271-1274
    • Van Laecke, S.1    Van Biesen, W.2
  • 324
    • 85011579203 scopus 로고    scopus 로고
    • Patients with hypertensionassociated thrombotic microangiopathy may present with complement abnormalities
    • Timmermans S et al. Patients with hypertensionassociated thrombotic microangiopathy may present with complement abnormalities. Kidney Int 2017;91:1420-1425
    • (2017) Kidney Int , vol.91 , pp. 1420-1425
    • Timmermans, S.1
  • 325
    • 76649090941 scopus 로고    scopus 로고
    • Severe renal failure and microangiopathic hemolysis induced by malignant hypertension-case series and review of literature
    • Shavit L, Reinus C, Slotki I. Severe renal failure and microangiopathic hemolysis induced by malignant hypertension-case series and review of literature. Clin Nephrol 2010;73:147-152
    • (2010) Clin Nephrol , vol.73 , pp. 147-152
    • Shavit, L.1    Reinus, C.2    Slotki, I.3
  • 326
    • 84921646968 scopus 로고    scopus 로고
    • Drug-induced thrombotic microangiopathy: A systematic review of published reports
    • Al-Nouri ZL et al. Drug-induced thrombotic microangiopathy: a systematic review of published reports. Blood 2015;125:616-618
    • (2015) Blood , vol.125 , pp. 616-618
    • Al-Nouri, Z.L.1
  • 327
    • 84999881304 scopus 로고    scopus 로고
    • Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature
    • Kavanagh D et al. Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature. Blood 2016
    • (2016) Blood
    • Kavanagh, D.1
  • 328
    • 84896996710 scopus 로고    scopus 로고
    • Thrombotic microangiopathy associated with interferon beta
    • Hunt D et al. Thrombotic microangiopathy associated with interferon beta. N Engl J Med 2014;370:1270-1271
    • (2014) N Engl J Med , vol.370 , pp. 1270-1271
    • Hunt, D.1
  • 329
    • 40849130173 scopus 로고    scopus 로고
    • VEGF inhibition and renal thrombotic microangiopathy
    • Eremina V et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008;358:1129-1136
    • (2008) N Engl J Med , vol.358 , pp. 1129-1136
    • Eremina, V.1
  • 330
    • 84945437213 scopus 로고    scopus 로고
    • Thrombotic microangiopathy, cancer, and cancer drugs
    • Izzedine H, Perazella MA. Thrombotic microangiopathy, cancer, and cancer drugs. Am J Kidney Dis 2015;66:857-868
    • (2015) Am J Kidney Dis , vol.66 , pp. 857-868
    • Izzedine, H.1    Perazella, M.A.2
  • 331
    • 0018675341 scopus 로고
    • Microangiopathic hemolytic anemia and cancer: A review
    • Antman KH et al. Microangiopathic hemolytic anemia and cancer: a review. Medicine (Baltimore) 1979;58:377-384
    • (1979) Medicine (Baltimore) , vol.58 , pp. 377-384
    • Antman, K.H.1
  • 332
    • 80053633983 scopus 로고    scopus 로고
    • Systemic malignancies as a cause of unexpected microangiopathic hemolytic anemia and thrombocytopenia
    • George JN. Systemic malignancies as a cause of unexpected microangiopathic hemolytic anemia and thrombocytopenia. Oncology (Williston Park) 2011;25:908-914
    • (2011) Oncology (Williston Park) , vol.25 , pp. 908-914
    • George, J.N.1
  • 333
    • 77953717551 scopus 로고    scopus 로고
    • Complement factor H autoantibodies are associated with early stage NSCLC
    • Amornsiripanitch N et al. Complement factor H autoantibodies are associated with early stage NSCLC. Clin Cancer Res 2010;16:3226-3231
    • (2010) Clin Cancer Res , vol.16 , pp. 3226-3231
    • Amornsiripanitch, N.1
  • 334
    • 36049001153 scopus 로고    scopus 로고
    • Thrombotic microangiopathy as a complication in a patient with focal segmental glomerulosclerosis
    • Benz K et al. Thrombotic microangiopathy as a complication in a patient with focal segmental glomerulosclerosis. Pediatr Nephrol 2007;22:2125-2128
    • (2007) Pediatr Nephrol , vol.22 , pp. 2125-2128
    • Benz, K.1
  • 335
    • 0026649518 scopus 로고
    • Recurrent haemolytic uraemic syndrome in a boy with focal and segmental glomerulosclerosis
    • Bokenkamp A et al. Recurrent haemolytic uraemic syndrome in a boy with focal and segmental glomerulosclerosis. Eur J Pediatr 1992;151:791-792
    • (1992) Eur J Pediatr , vol.151 , pp. 791-792
    • Bokenkamp, A.1
  • 336
    • 84925620174 scopus 로고    scopus 로고
    • Podocyte dysfunction in atypical haemolytic uraemic syndrome
    • Noris M, Mele C, Remuzzi G. Podocyte dysfunction in atypical haemolytic uraemic syndrome. Nat Rev Nephrol 2015;11:245-252
    • (2015) Nat Rev Nephrol , vol.11 , pp. 245-252
    • Noris, M.1    Mele, C.2    Remuzzi, G.3
  • 337
    • 0029826567 scopus 로고    scopus 로고
    • Development of focal segmental sclerosis and hyalinosis in hemolytic uremic syndrome
    • Caletti MG, Gallo G, Gianantonio CA. Development of focal segmental sclerosis and hyalinosis in hemolytic uremic syndrome. Pediatr Nephrol 1996;10:687-692
    • (1996) Pediatr Nephrol , vol.10 , pp. 687-692
    • Caletti, M.G.1    Gallo, G.2    Gianantonio, C.A.3
  • 338
    • 33845387138 scopus 로고    scopus 로고
    • A clinicopathologic study of thrombotic microangiopathy in the setting of IgA nephropathy
    • Chang A et al. A clinicopathologic study of thrombotic microangiopathy in the setting of IgA nephropathy. Clin Nephrol 2006;66:397-404
    • (2006) Clin Nephrol , vol.66 , pp. 397-404
    • Chang, A.1
  • 339
    • 84855583592 scopus 로고    scopus 로고
    • A clinicopathologic study of thrombotic microangiopathy in IgA nephropathy
    • El Karoui K et al. A clinicopathologic study of thrombotic microangiopathy in IgA nephropathy. J Am Soc Nephrol 2012;23:137-148
    • (2012) J Am Soc Nephrol , vol.23 , pp. 137-148
    • El Karoui, K.1
  • 340
    • 84980332096 scopus 로고    scopus 로고
    • Insights into kidney diseases from genome-wide association studies
    • Wuttke M, Kottgen A. Insights into kidney diseases from genome-wide association studies. Nat Rev Nephrol 2016;12:549-562
    • (2016) Nat Rev Nephrol , vol.12 , pp. 549-562
    • Wuttke, M.1    Kottgen, A.2
  • 341
    • 84929169595 scopus 로고    scopus 로고
    • Clinicopathologic characteristics and outcomes of renal thrombotic microangiopathy in antineutrophil cytoplasmic autoantibody-associated glomerulonephritis
    • Chen SF et al. Clinicopathologic characteristics and outcomes of renal thrombotic microangiopathy in antineutrophil cytoplasmic autoantibody-associated glomerulonephritis. Clin J Am Soc Nephrol 2015;10:750-758
    • (2015) Clin J Am Soc Nephrol , vol.10 , pp. 750-758
    • Chen, S.F.1
  • 342
    • 0018137313 scopus 로고
    • Haemolytic uraemic syndrome and idiopathic membranous glomerulonephritis
    • Dische FE, Culliford EJ, Parsons V. Haemolytic uraemic syndrome and idiopathic membranous glomerulonephritis. Br Med J 1978;1:1112-1113
    • (1978) Br Med J , vol.1 , pp. 1112-1113
    • Dische, F.E.1    Culliford, E.J.2    Parsons, V.3
  • 343
    • 0025972826 scopus 로고
    • Recurrent thrombotic thrombocytopenic purpura associated with membranous glomerulopathy
    • Friedlander MA, Jacobs GH. Recurrent thrombotic thrombocytopenic purpura associated with membranous glomerulopathy. Am J Kidney Dis 1991;17:83-85
    • (1991) Am J Kidney Dis , vol.17 , pp. 83-85
    • Friedlander, M.A.1    Jacobs, G.H.2
  • 344
    • 84921437508 scopus 로고    scopus 로고
    • Characterization of a factor H mutation that perturbs the alternative pathway of complement in a family with membranoproliferative GN
    • Wong EK et al. Characterization of a factor H mutation that perturbs the alternative pathway of complement in a family with membranoproliferative GN. J Am Soc Nephrol 2014;25:2425-2433
    • (2014) J Am Soc Nephrol , vol.25 , pp. 2425-2433
    • Wong, E.K.1
  • 345
    • 84863511490 scopus 로고    scopus 로고
    • A hybrid CFHR3-1 gene causes familial C3 glomerulopathy
    • Malik TH et al. A hybrid CFHR3-1 gene causes familial C3 glomerulopathy. J Am Soc Nephrol 2012;23:1155-1160
    • (2012) J Am Soc Nephrol , vol.23 , pp. 1155-1160
    • Malik, T.H.1
  • 346
    • 33745697887 scopus 로고    scopus 로고
    • Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II)
    • Licht C et al. Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II). Kidney Int 2006;70:42-50
    • (2006) Kidney Int , vol.70 , pp. 42-50
    • Licht, C.1
  • 347
    • 84862301748 scopus 로고    scopus 로고
    • Factor H autoantibodies in membranoproliferative glomerulonephritis
    • Goodship TH et al. Factor H autoantibodies in membranoproliferative glomerulonephritis. Mol Immunol 2012;52:200-206
    • (2012) Mol Immunol , vol.52 , pp. 200-206
    • Goodship, T.H.1
  • 348
    • 77956394517 scopus 로고    scopus 로고
    • Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis
    • Gale DP et al. Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet 2010;376:794-801
    • (2010) Lancet , vol.376 , pp. 794-801
    • Gale, D.P.1
  • 349
    • 40849147541 scopus 로고    scopus 로고
    • Complement factor H deficiency and posttransplantation glomerulonephritis with isolated C3 deposits
    • Boyer O et al. Complement factor H deficiency and posttransplantation glomerulonephritis with isolated C3 deposits. Am J Kidney Dis 2008;51:671-677
    • (2008) Am J Kidney Dis , vol.51 , pp. 671-677
    • Boyer, O.1
  • 350
    • 80155136247 scopus 로고    scopus 로고
    • Three kidneys, two diseases, one antibody?
    • Lorcy N et al. Three kidneys, two diseases, one antibody? Nephrol Dial Transplant 2011;26:3811-3813
    • (2011) Nephrol Dial Transplant , vol.26 , pp. 3811-3813
    • Lorcy, N.1
  • 351
    • 0346656641 scopus 로고    scopus 로고
    • Familial mesangio-capillary glomerulonephritis with initial presentation as haemolytic uraemic syndrome
    • Cooper M et al. Familial mesangio-capillary glomerulonephritis with initial presentation as haemolytic uraemic syndrome. Nephrol Dial Transplant 2004;19:230-233
    • (2004) Nephrol Dial Transplant , vol.19 , pp. 230-233
    • Cooper, M.1
  • 352
    • 84982915216 scopus 로고    scopus 로고
    • Renal thrombotic microangiopathy in proliferative lupus nephritis: Risk factors and clinical outcomes: A case-control study
    • Barrera-Vargas A et al. Renal thrombotic microangiopathy in proliferative lupus nephritis: risk factors and clinical outcomes: a case-control study. J Clin Rheumatol 2016;22:235-240
    • (2016) J Clin Rheumatol , vol.22 , pp. 235-240
    • Barrera-Vargas, A.1
  • 353
    • 84860763334 scopus 로고    scopus 로고
    • Evaluation of clinical outcomes and renal vascular pathology among patients with lupus
    • Barber C et al. Evaluation of clinical outcomes and renal vascular pathology among patients with lupus. Clin J Am Soc Nephrol 2012;7:757-764
    • (2012) Clin J Am Soc Nephrol , vol.7 , pp. 757-764
    • Barber, C.1
  • 354
    • 84939541475 scopus 로고    scopus 로고
    • Thrombotic microangiopathy and poor renal outcome in lupus patients with or without antiphospholipid syndrome
    • Hernandez-Molina G et al. Thrombotic microangiopathy and poor renal outcome in lupus patients with or without antiphospholipid syndrome. Clin Exp Rheumatol 2015;33:503-508
    • (2015) Clin Exp Rheumatol , vol.33 , pp. 503-508
    • Hernandez-Molina, G.1
  • 355
    • 84952013335 scopus 로고    scopus 로고
    • Recent developments in the classification, evaluation, pathophysiology, and management of scleroderma renal crisis
    • Ghossein C, Varga J, Fenves AZ. Recent developments in the classification, evaluation, pathophysiology, and management of scleroderma renal crisis. Curr Rheumatol Rep 2016;18:5
    • (2016) Curr Rheumatol Rep , vol.18 , pp. 5
    • Ghossein, C.1    Varga, J.2    Fenves, A.Z.3
  • 356
    • 85038010060 scopus 로고    scopus 로고
    • Highly specialised technologies: Eculizumab for treating atypical haemolytic uraemic syndrome
    • National Institute for Health and Care Excellence
    • National Institute for Health and Care Excellence. Highly specialised technologies: Eculizumab for treating atypical haemolytic uraemic syndrome. NICE 2015, p. 7
    • (2015) NICE , pp. 7


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.